

STATISTICAL BRIEF #249

March 2019

Inpatient Stays Involving Mental and Substance Use Disorders, 2016

Pamela L. Owens, Ph.D., Kathryn R. Fingar, Ph.D., M.P.H., Kimberly W. McDermott, Ph.D., Pradip K. Muhuri, Ph.D., and Kevin C. Heslin, Ph.D.

Introduction

Mental and substance use disorders are common in the United States. In 2016, over 55 million people aged 18 years and over (more than one in five adults) suffered from mental and/or substance use disorders (MSUDs).¹ Of these adults, nearly 45 million had a mental disorder alone, 11 million had a substance use disorder alone, and 8 million had both a mental disorder and a substance use disorder.²

Not only do mental and substance use disorders co-occur, they also are linked to other physical conditions such as diabetes, heart disease, and asthma.^{3,4} Disorders such as depression, anxiety, and substance use disorder are associated with significant distress and impairment, including complications with multiple chronic conditions, disability, inability to function in society, and substantial economic costs.^{5,6} The treatment costs of mental disorders alone totaled \$201 billion in 2013.⁷ Taking into account additional costs associated with lost work productivity and disability payments, the total cost of mental and substance use disorders to society is estimated to be more than twice that amount.⁸

¹ Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Key Substance Use and Mental Health Indicators in the United States: Results From the 2016 National Survey on Drug Use and Health. 2017. www.samhsa.gov/data/sites/default/files/NSDUH-FFR1-2016/NSDUH-FFR1-2016.htm#adol1. Accessed November 26, 2018.

² Ibid.

³ Owens PL, Heslin KC, Fingar KR, Weiss AJ. Co-occurrence of Physical Health Conditions and Mental Health and Substance Use Conditions Among Adult Inpatient Stays, 2010 Versus 2014. HCUP Statistical Brief #240. June 2018. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb240-Co-occurring-Physical-Mental-Substance-Conditions-Hospital-Stays.pdf. Accessed December 13, 2018.

⁴ Kaiser Family Foundation. Facilitating Access to Mental Health Services: A Look at Medicaid, Private Insurance, and the Uninsured. November 27, 2017. www.kff.org/medicaid/fact-sheet/facilitating-access-to-mental-health-services-a-look-at-medicaid-private-insurance-and-the-uninsured/. Accessed November 12, 2018.

⁵ Ibid.

⁶ Kamal R, Cox C, Rousseau D, et al. Costs and Outcomes of Mental Health and Substance Use Disorders in the US. JAMA. 2017;318(5):415.

⁷ Roehrig C. Mental Disorders Top the List of the Most Costly Conditions in the United States: \$201 Billion. Health Affairs. 2016;35(6):1130–5.

⁸ Insel T. Post by Former NIMH Director Thomas Insel: Mental Health Awareness Month: By the Numbers. 2015. www.nimh.nih.gov/about/directors/thomas-insel/blog/2015/mental-health-awareness-month-by-the-numbers.shtml. Accessed November 26, 2018.

Highlights

- In 2016, nearly 10 million inpatient stays had a principal (2.2 million) or secondary (7.7 million) MSUD diagnosis, constituting 6.1 and 21.7 percent of all inpatient stays, respectively.
- In total, stays principally for MSUDs cost \$15.3 billion (3.6 percent of total hospital costs). On average, stays for MSUDs cost \$7,100 and were 6.4 days.
- The rate of stays principally for MSUDs was highest among adults aged 18–64 years.
- Nearly 60 percent of MSUD stays for patients aged less than 65 years were billed to public payers.
- One in four stays principally for MSUDs were for depressive disorders. Alcohol-related disorders and schizophrenia each constituted nearly one in five MSUD stays.
- Although uncommon, stays for eating disorders were the costliest (\$19,400 per stay) and the longest (14 days, on average) type of MSUD stay. Inpatient stays for schizophrenia were the second costliest (\$8,900 per stay) and second longest (11 days on average) MSUD stay.
- The most common reason for MSUD stays among males aged 45–64 years was alcohol-related disorders. Schizophrenia was the most common reason for MSUD stays for males aged 18–44 years.

This Healthcare Cost and Utilization Project (HCUP) Statistical Brief presents statistics from the 2016 National Inpatient Sample (NIS) on inpatient stays involving MSUDs at community hospitals among patients aged 5 years or older. First, MSUD-related inpatient stay characteristics, including costs, length of stay, discharge status, patient demographics, primary expected payer, and hospital location are shown. Inpatient stays for MSUDs (i.e., those with a principal MSUD diagnosis) are shown separately from those with a principal diagnosis of a physical condition and a secondary MSUD condition. Stays with no MSUD diagnosis are shown as a point of comparison. Second, the frequency, costs, and length of stay for specific MSUDs are shown. Because of the large sample size of the HCUP NIS, small differences can be statistically significant. Thus, only percentage differences between groups greater than or equal to 10 percent are noted in the text. For further information on the methodology, see the Data Source and Definitions sections at the end of this Statistical Brief.

Findings

Characteristics of inpatient stays with and without a principal or secondary MSUD diagnosis, 2016

Table 1 presents utilization and cost statistics for inpatient stays related to MSUDs in 2016. Stays with a principal MSUD diagnosis are shown separately from stays with an MSUD diagnosis that was secondary to other principal physical diagnoses. These stays are compared with those without an MSUD diagnosis.

Table 1. Characteristics of inpatient stays with and without a principal or secondary MSUD diagnosis, 2016

Inpatient stay characteristic	Principal MSUD diagnosis	Secondary MSUD diagnosis	No MSUD diagnosis
Stays, N	2,169,000	7,726,500	25,779,900
Stays, %	6.1	21.7	72.3
Stays, rate per 100,000 population	717	2,555	8,524
Aggregate costs, \$ billions	15.3	110.3	296.4
Aggregate costs, %	3.6	26.1	70.2
Mean cost per stay, \$	7,100	14,300	11,500
Mean cost per day, \$	1,400	3,400	3,200
Mean length of stay, days	6.4	5.4	4.2
Admitted from emergency department, %	60.4	66.3	46.3
Discharge status, %			
Discharged home or to home health care	82.2	72.7	83.3
Transferred to short-term hospital	2.0	2.1	1.9
Transferred to other type of facility	11.3	20.7	12.1
Died in hospital	0.5	2.1	2.0
Other	3.9	2.5	0.8

Abbreviation: MSUD, mental and/or substance use disorder

Notes: The number of stays and mean cost per stay and per day were rounded to the nearest hundred. Stays with a principal MSUD diagnosis are mutually exclusive from those with a secondary MSUD diagnosis. Population rates are based on population estimates for persons aged 5 years and older. Population data were obtained from Claritas. Other discharge status includes discharged against medical advice and discharged alive, destination unknown.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

- **In 2016, there were nearly 10 million stays with a principal or secondary MSUD diagnosis, constituting more than 1 in 4 inpatient stays.**

In 2016, there were 9,895,500 inpatient stays with a principal (2.2 million) or secondary (7.7 million) MSUD. Combined, stays with a principal (6.1 percent) or secondary (21.7 percent) MSUD were 27.8 percent of the 35.7 million total inpatient stays.

- **Stays with a secondary MSUD diagnosis cost more and were longer than stays without an MSUD diagnosis.**

Stays for a principal MSUD accounted for 6.1 percent of all adult stays and 3.6 percent of total hospital costs (\$15.3 billion), pointing to the relatively low resource intensity of MSUD care in community hospitals. On average, stays with a principal MSUD cost \$7,100 with an average length of stay of 6.4 days.

Care for adults with a physical condition as a principal diagnosis and a coexisting MSUD accounted for roughly 22 percent of hospital stays and 26 percent of hospital costs, whereas care for adults with only physical conditions accounted for 72 percent of all stays and 70 percent of hospital costs. Stays with a coexisting MSUD cost a total of \$110.3 billion, with an average cost of \$14,300 and an average length of stay of 5.4 days. On average, stays for a physical condition without an MSUD cost \$11,500 and were 4.2 days long. This suggests a higher resource intensity when stays for physical conditions coexist with MSUDs.

- **Inpatient stays involving MSUDs were more likely to be admitted from the emergency department than other stays.**

Compared with stays without an MSUD diagnosis, a greater percentage of stays with a principal or secondary MSUD were admitted through the emergency department (46.3 vs. 60.4 and 66.3 percent, respectively).

- **Inpatient stays with a principal MSUD were less likely to result in in-hospital death than were other stays.**

Stays with a principal MSUD were less likely to result in in-hospital death compared with other stays (0.5 vs. 2 percent). In addition, stays with a secondary MSUD were less likely to be discharged routinely to home or to home health care (72.7 vs. 82–83 percent) and more likely to be transferred to a facility other than a short-term hospital, such as a skilled nursing facility or other long-term care facility (20.7 vs. 11–12 percent), compared with stays with a principal or no MSUD diagnosis.

Table 2 presents the percentage and rates of inpatient stays with and without an MSUD diagnosis for select patient sociodemographic characteristics. Stays with a principal MSUD diagnosis are shown separately from stays with a secondary MSUD diagnosis. These stays are compared with those without an MSUD diagnosis.

Table 2. Patient characteristics and hospital location of inpatient stays with and without a principal or secondary MSUD diagnosis, 2016

Characteristic	Principal MSUD diagnosis (N=2,169,000)		Secondary MSUD diagnosis (N=7,726,500)		No MSUD Diagnosis (N=25,779,900)	
	Stays, %	Rate of stays per 100,000 population	Stays, %	Rate of stays per 100,000 population	Stays, %	Rate of stays per 100,000 population
Overall total	100.0	717	100.0	2,555	100.0	8,524
Age group, years						
5–17	7.9	317	1.2	169	20.3	9,676
18–44	49.2	923	21.2	1,417	23.3	5,195
45–64	34.6	892	38.1	3,494	19.7	6,040
65–74	5.7	440	19.6	5,373	14.9	13,596
75+	2.6	272	19.9	7,540	21.8	27,603
Sex						
Female	46.6	656	58.3	2,926	57.1	9,563
Male	53.4	780	41.7	2,167	42.9	7,439
Community-level income						
Quartile 1 (lowest)	35.1	963	32.0	3,170	29.9	9,921
Quartile 2	25.4	732	26.2	2,717	25.2	8,762
Quartile 3	22.2	604	23.7	2,324	24.1	7,943
Quartile 4 (highest)	17.3	481	18.1	1,817	20.7	6,957
Primary expected payer						
Less than 65 years						
Medicare	17.2	N/A	24.3	N/A	8.2	N/A
Medicaid	41.2	N/A	32.9	N/A	35.0	N/A
Private insurance	27.3	N/A	32.1	N/A	47.6	N/A
Self-pay/no charge	9.7	N/A	7.0	N/A	5.5	N/A
Other	4.6	N/A	3.7	N/A	3.7	N/A
65+ years						
Medicare	86.0	N/A	90.1	N/A	88.8	N/A
Non-Medicare	14.0	N/A	9.9	N/A	11.2	N/A
Patient residence						
Rural	13.9	683	16.6	2,938	16.0	9,458
Urban	86.1	709	83.4	2,474	84.0	8,334
Hospital location						
Northeast	23.0	938	18.6	2,698	18.1	8,763
New England	5.9	921	5.5	3,027	4.3	7,854
Middle Atlantic	17.1	943	13.1	2,580	13.8	9,087
Midwest	25.3	860	24.1	2,921	21.4	8,644
East North Central	16.8	826	16.9	2,963	14.7	8,626
West North Central	8.5	935	7.3	2,828	6.7	8,685
South	35.5	677	38.0	2,579	40.0	9,050
South Atlantic	21.1	765	20.8	2,687	20.5	8,856
East South Central	6.3	769	7.2	3,129	6.8	9,830
West South Central	8.2	487	10.1	2,134	12.7	8,987
West	16.1	490	19.3	2,083	20.5	7,401
Mountain	5.3	521	6.2	2,190	6.3	7,374
Pacific	10.8	476	13.0	2,035	14.2	7,413

Abbreviations: MSUD, mental and/or substance use disorder; N/A, not available.

Notes: Stays with a principal MSUD diagnosis are mutually exclusive from those with a secondary MSUD diagnosis. Population rates are based on population estimates for individuals aged 5 years and older. Population data were obtained from Claritas.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

- **Over 80 percent of stays principally for an MSUD were for adults aged 18–44 years or 45–64 years.**

Over four out of five stays (83.8 percent) principally for MSUDs were for 18–44 year olds and 45–64 year olds. In contrast, these age groups accounted for nearly three out of five stays (59.3 percent) with a secondary MSUD and two out of five stays (43.0 percent) without an MSUD.

The majority of stays with a coexisting MSUD were for adults aged 18–44 years (21.2 percent) or 45–64 years (38.1 percent). Nearly one in five stays with a coexisting MSUD were for older adults aged 65–74 years (19.6 percent) or 75 years and older (19.9 percent). Fewer than 2 percent of stays with a coexisting MSUD were for children aged 5–17 years (1.2 percent).

No age group accounted for a disproportionate share of stays with a physical condition without an MSUD: 5–17 years (20.3 percent), 18–44 years (23.3 percent), 45–64 years (19.7 percent), 65–74 years (14.9 percent), 75+ years (21.8 percent).

- **The rate of inpatient stays principally for MSUDs was highest among adults aged 18–44 and 45–64 years and among males.**

The rate of stays with a principal MSUD was at least twice as high among adults aged 18–44 and 45–64 years (923 and 892 per 100,000 population, respectively) compared with all other age groups: (5–17 years: 317; 65–74 years: 440; 75+ years: 272 per 100,000 population). The rate of stays with a secondary MSUD increased steadily with age. The oldest adults had the highest rate of stays with a coexisting MSUD (7,540 per 100,000 population among adults aged 75 years and older).

Among individuals aged 5–17 years, the rate of stays with a principal MSUD was higher than the rate of stays for a secondary MSUD. Among the older age groups, however, the rate of stays with a secondary MSUD was higher than the rate of stays with a principal MSUD and this difference increased with age: 923 versus 1,417 per 100,000 adults aged 18–44 years (1.5 times greater) and 272 versus 7,540 per 100,000 adults aged 75+ years (28 times greater).

The rate of stays with a principal MSUD was higher among males than among females (780 vs. 656 per 100,000 population). By contrast, the rate of stays with a secondary MSUD was higher among females than among males (2,926 vs. 2,167 per 100,000 population).

- **Nearly 60 percent of stays involving MSUDs among patients less than 65 years old were billed to public payers.**

In total, 58.4 percent of stays for patients aged less than 65 years with a principal MSUD were billed to Medicare (17.2 percent) or Medicaid (41.2 percent). Similarly, 57.2 percent of stays for patients aged less than 65 years with a secondary MSUD were billed to Medicare (24.3 percent) or Medicaid (32.9 percent). In contrast, only 43.2 percent of non-MSUD stays for patients aged less than 65 years were billed to public payers. This lower overall public share was mainly due to a much smaller percentage billed to Medicare (8.2 percent).

- **Nearly 1 in 10 stays with a principal MSUD among patients aged less than 65 years were billed as self-pay or no charge.**

Among patients aged less than 65 years, nearly 10 percent of stays with a principal diagnosis for an MSUD were billed as self-pay or no charge, compared with 7.0 percent of stays in this age group with a secondary MSUD and 5.5 percent of stays without an MSUD.


- **The geographic distribution of rates of stays differed according to whether the MSUD was a principal or secondary diagnosis.**

Whereas the rate of stays with a principal MSUD was similar in rural and urban areas (683 and 709 per 100,000 population, respectively), the rate of stays with a secondary MSUD was higher in rural than in urban areas (2,938 vs. 2,474 per 100,000 population).

The rate of stays with a principal MSUD was highest in the Northeast region, with rates in both the New England and the Middle Atlantic census divisions over 900 per 100,000 population. The rate of stays with a secondary MSUD diagnosis was highest in the Midwest region (2,921 per 100,000 population), although specific divisions within the South and the Northeast had higher overall rates (East South Central division: 3,129; New England division: 3,027). Both the rate of stays with a principal and the rate of stays with a secondary MSUD diagnosis were lowest in the West (490 and 2,083 per 100,000 population, respectively).

Figure 1 displays the percentage of all inpatient stays with and without an MSUD diagnosis, by primary expected payer and age group in 2016.

Figure 1. Percentage of all inpatient stays with and without a principal or secondary MSUD diagnosis, by primary expected payer and age group, 2016



Abbreviation: MSUD, mental and/or substance use disorder

Note: Stays with a principal MSUD diagnosis are mutually exclusive from those with a secondary MSUD diagnosis.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

- **Over half of all Medicare-billed stays for patients aged less than 65 years involved an MSUD.**

In 2016, MSUD-related stays accounted for 52.3 percent of Medicare-billed inpatient stays for patients under 65 years (principal MSUD: 12.1 percent; secondary MSUD: 40.2 percent). MSUD stays for patients under 65 years accounted for 21 to 37 percent of the stays billed to non-Medicare payers (Medicaid: 29.3 percent; private insurance: 20.8 percent; self-pay/no charge: 36.7 percent; other payers: 30.3 percent).

In contrast, only one-fourth of Medicare-billed stays for patients aged 65 years and older involved an MSUD (principal: 1.4 percent; secondary: 24.3 percent).


- **Among patients aged less than 65 years old, over 10 percent of stays were principally for an MSUD, except for those billed to private insurance.**

Only 5.5 percent of stays billed to private insurance were principally for an MSUD, whereas 10–14 percent of stays billed to other expected payers were principally for an MSUD (Medicare, 12.1 percent; Medicaid, 10.2 percent; self-pay/no charge, 13.6 percent; other payers, 10.5 percent).

Frequency, costs, and length of specific MSUD inpatient stays, 2016

Figure 2 displays rates of inpatient stays by specific MSUD disorders in 2016, according to whether the disorder was a principal or secondary diagnosis.

Figure 2. Rates of stays^a for specific MSUD disorders, by principal and secondary diagnosis, 2016



Abbreviation: MSUD, mental and/or substance use disorder

Notes: Suicidal includes suicidal ideation and attempts. Secondary diagnoses are counted only if the record had a non-MSUD diagnosis listed as the principal diagnosis. Population rates are based on population estimates for persons 5 years and older. Population data are obtained from Claritas.

^a Rate of stays per 100,000 population.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

- **In 2016, the most common type of principal and secondary substance-related diagnosis among inpatient stays was alcohol-related disorders, followed by opioid-related disorders.**

The most common type of a substance use disorder stay was alcohol-related disorders, with a rate of 133 stays per 100,000 population as a principal diagnosis and 372 stays per 100,000 population as a coexisting disorder. The second most common type of substance use disorder among stays was opioid-related disorders (principal: 48; secondary: 214 per 100,000 population).

The least common reason for a substance use disorder stay was cannabis-related disorders (3 stays per 100,000 population), but as a secondary diagnosis, cannabis-related disorders was the third most common type of substance use disorder stay (147 per 100,000 population).

- **Depressive disorders and schizophrenia were the most common reasons for a mental disorder stay, whereas anxiety disorders and depressive disorders were the most common coexisting mental disorders for inpatient stays.**


The most common reason for a mental disorder stay was depressive disorders (187 stays per 100,000 population). Along with anxiety disorders (1,132 stays per 100,000 population), depressive disorders was one of the most common secondary diagnoses for inpatient stays with a coexisting mental disorder (1,115 per 100,000 population). Although anxiety disorders was one of the most common coexisting mental disorders, stays principally for these disorders were much less common (9 per 100,000 population) than those for depressive disorders.

The second most common reason for a mental disorder stay and the fourth most common secondary diagnosis for inpatient stays with a coexisting mental disorder was schizophrenia and related disorders (131 and 126 per 100,000 population, respectively).

Suicidal ideation or attempt was more likely to be the reason for a mental disorder stay than a stay with a secondary mental disorder (41 vs. 25 stays per 100,000 population, respectively).

Figure 3 displays the percentage of inpatient stays for each MSUD diagnosis in 2016, out of all stays principally for an MSUD, as indicated by the size of each circle. The average cost and length of each type of stay are shown on the x-axis and y-axis, respectively. The exact estimates of costs and length of stay are included in Appendix A at the end of this Statistical Brief.

Figure 3. Percentage, cost, and length of inpatient stays principally for an MSUD, by specific disorder, 2016



Abbreviation: MSUD, mental and/or substance use disorder

Note: Suicidal includes suicidal ideation and attempts. Disorders shown are based on the principal diagnosis.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

■ **In 2016, more than one in four inpatient stays with a principal MSUD were for depressive disorders.**


The most common type of disorder among inpatient stays with a principal MSUD in 2016 was depressive disorders, constituting 26.1 percent of these stays. Alcohol-related disorders and schizophrenia and related disorders each accounted for nearly one in five stays principally for an MSUD, followed by bipolar disorders (12.5 percent), opioid-related disorders (6.7 percent), and suicidal ideation or attempt (5.7 percent).

- Although uncommon, inpatient stays for eating disorders were the costliest and longest type of stays for MSUDs.

Although inpatient stays with a principal diagnosis of eating disorders constituted only 0.3 percent of all stays with a principal MSUD, on average they cost \$19,400 and lasted 13.6 days. Inpatient stays for schizophrenia and related disorders were the second costliest and second longest type of stay for MSUDs, with a mean cost per stay of \$8,900 and a mean length of stay of 10.5 days. Stays for alcohol-related disorders were the third costliest (\$8,800 per stay), and those for bipolar disorders were the third longest (7.6 days) type of stays with a principal MSUD.

Figure 4 displays types of disorders among inpatient stays with a principal MSUD diagnosis in 2016, by patient sex and age. The five most common principal MSUD diagnoses are shown as distinct categories. These diagnoses include depressive disorders, alcohol-related disorders, schizophrenia and related disorders, bipolar disorders, and opioid-related disorders. All other types of MSUD diagnoses are included in the Other category.

Figure 4. Distribution of stays for specific principal MSUD diagnoses, by patient sex and age, 2016



Abbreviation: MSUD, mental or substance use disorder

Note: Disorders shown are based on the frequency of stays principally for an MSUD. Other includes cannabis-related disorders; miscellaneous substances and addictive disorders; sedative-related disorders; stimulant-related disorders; anxiety disorders; disruptive, impulse-control, and conduct disorders; eating disorders; obsessive-compulsive disorders; miscellaneous mental disorders; personality disorders; somatic symptom disorders; suicidal ideation or attempt; and trauma- and stressor-related disorders.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

- **In 2016, the most common reason for MSUD stays among the youngest and oldest age groups among both males and females was depressive disorders.**

Over half of MSUD stays for males and females aged 5–17 years (53.2 and 60.7 percent, respectively), and over one-third of those for males and females aged 75 years or older (35.1 and 37.9 percent, respectively) were for depressive disorders (vs. 18.3–28.3 percent of stays for patients in the other age-sex groups). The most common reason for MSUD stays for males aged 5–17 years and 75 years or older, and for females of all ages was depressive disorders.

Among stays for every age group younger than 75 years, depressive disorders constituted a greater percentage of MSUD stays for females than for males (e.g., 28.3 vs. 20.5 percent of stays for patients aged 65–74 years).

- **Alcohol-related disorders was the most common type of principal MSUD stay for males aged 45–64 years and, at every age, was a more common reason for male hospitalization than for female hospitalization.**

Over one-third (37–38 percent) of MSUD stays for males aged 45–74 years were for alcohol-related disorders. Among MSUD stays for females, alcohol-related disorders was a more common reason for a stay among patients aged 45–74 years (12.7–18.6 percent) than for a stay for patients in the other age groups (0.3–8.6 percent).

Among MSUD stays for patients of every age group, alcohol-related disorders constituted a greater percentage of MSUD stays for males than for females (e.g., 37.2 vs. 12.7 percent among stays for patients aged 65–74 years).

- **Schizophrenia was the most common type of principal MSUD stay for males aged 18–44 years.**

The most common type of principal MSUD stay for males aged 18–44 years was schizophrenia and related disorders, constituting 24.7 percent of all stays principally for an MSUD. A principal diagnosis of schizophrenia was more common among stays for males aged 5–17 and 18–44 years than among stays for females in the same age group (5–17 years: 4.8 vs. 1.9 percent, respectively; 18–44 years: 24.7 vs. 14.1 percent, respectively). In contrast, among MSUD stays for older adults, a principal diagnosis of schizophrenia and related disorders was more common among stays for females aged 64–74 and 75+ years than among stays for males in the same age group (64–74 years: 22.5 vs. 17.1 percent, respectively; 75+ years: 21.4 vs. 18.0 percent, respectively).

- **MSUD stays for adult females were more likely than stays for males to have a principal diagnosis of bipolar disorders.**

Except for MSUD stays for patients aged 5–17 years, a principal diagnosis of bipolar disorders was more common for females than for males in each age group (e.g., 15–16 vs. 9 percent of stays for patients aged 45–74 years). The percentage of stays for bipolar disorders ranged from a low of 6.6 percent of stays among males aged 75+ years to a high of 16.3 percent of stays for females aged 18–44 years.

- **Opioid-related disorders constituted nearly 10 percent of all MSUD stays for males aged 18–44 years and females aged 65 years or older.**

Among MSUD stays for males aged 18–44 years, 8.9 percent were for opioids. Among MSUD stays for females, opioid-related disorders were highest among stays for those in the oldest age groups (9 percent of MSUD stays among females older than 64 years). Generally, a higher percentage of MSUD stays for younger than for older patients had a principal diagnosis categorized as Other disorders⁹ (i.e., disorders that were less common than the top five principal MSUD diagnoses).

⁹ Other disorders include cannabis-related disorders; miscellaneous substances and addictive disorders; sedative-related disorders; stimulant-related disorders; anxiety disorders; disruptive, impulse-control, and conduct disorders; eating disorders; obsessive-

Appendix A. Number, percentage, cost, and length of inpatient stays for a specific MSUD diagnosis, 2016

Principal MSUD	Stays, N	All MSUD stays, %	Mean cost per stay, \$	Aggregate costs, \$ billions	Mean length of stay, days
Any principal MSUD diagnosis	2,169,000	100	7,100	15.3	6.4
Any principal substance use disorder-related diagnosis					
Alcohol-related disorders	401,300	18.5	8,800	3.5	4.9
Opioid-related disorders	146,300	6.7	6,400	0.9	4.2
Stimulant-related disorders	49,400	2.3	7,400	0.4	4.4
Miscellaneous substances and addictive disorders	38,800	1.8	4,900	0.2	4.0
Sedative-related disorders	12,100	0.6	5,700	0.1	4.5
Cannabis-related disorders	9,100	0.4	6,500	0.1	5.2
Any principal mental disorder-related diagnosis					
Depressive disorders	566,700	26.1	5,300	3.0	6.1
Schizophrenia and related disorders	394,800	18.2	8,900	3.5	10.5
Bipolar disorders	270,900	12.5	6,500	1.8	7.6
Suicidal ideation or attempt	123,500	5.7	7,900	1.0	3.5
Trauma- and stressor-related disorders	57,500	2.7	4,200	0.2	4.2
Anxiety disorders	27,100	1.2	5,100	0.1	4.2
Miscellaneous mental disorders	26,600	1.2	5,200	0.1	4.4
Disruptive, impulse-control, and conduct disorders	16,900	0.8	6,500	0.1	7.5
Personality disorders	10,500	0.5	6,300	0.1	6.7
Somatic symptom disorders	10,500	0.5	7,600	0.1	3.4
Eating disorders	5,800	0.3	19,400	0.1	13.6
Obsessive-compulsive disorders	1,200	0.1	7,200	0.0 ^a	7.3

Abbreviation: MSUD, mental or substance use disorder

^a Aggregate costs of stays for obsessive-compulsive disorders totaled 0.0087 billion dollars.

Note: The estimates of costs and length of stay in this table correspond to the conditions displayed in Figure 3.

Source: Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP), National Inpatient Sample (NIS), 2016

compulsive disorders; miscellaneous mental disorders; personality disorders; somatic symptom disorders; suicidal ideation or attempt; and trauma- and stressor-related disorders.

About Statistical Briefs

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs provide basic descriptive statistics on a variety of topics using HCUP administrative health care data. Topics include hospital inpatient, ambulatory surgery, and emergency department use and costs, quality of care, access to care, medical conditions, procedures, and patient populations, among other topics. The reports are intended to generate hypotheses that can be further explored in other research; the reports are not designed to answer in-depth research questions using multivariate methods.

Data Source

The estimates in this Statistical Brief are based upon data from the HCUP 2016 National Inpatient Sample (NIS). Supplemental sources included population denominator data for use with HCUP databases, derived from information available from Claritas, a vendor that produces population estimates and projections based on data from the U.S. Census Bureau.¹⁰

Definitions

Diagnoses and ICD-10-CM

The *principal diagnosis* is that condition established after study to be chiefly responsible for the patient's admission to the hospital. *Secondary diagnoses* are concomitant conditions that coexist at the time of admission or develop during the stay.

In this Statistical Brief, we created mutually exclusive categories for stays with a principal MSUD diagnosis (i.e., referred to as *MSUD stays* or *stays principally for an MSUD*) and those with one or more MSUD diagnoses secondary to a principal diagnosis of a physical health condition (i.e., referred to as *MSUD-related stays*, *stays with a coexisting MSUD*, or *stays with a secondary MSUD*).

ICD-10-CM is the International Classification of Diseases, Tenth Revision, Clinical Modification coding system. In October 2015, ICD-10-CM replaced the ICD-9-CM diagnosis coding system with the ICD-10-CM diagnosis coding system for most inpatient and outpatient medical encounters. There are over 70,000 ICD-10-CM diagnosis codes.

Case definition

The ICD-10-CM codes defining MSUD can be found in Appendix B, available as a separate supplemental file associated with this Statistical Brief on the HCUP-US website at www.hcup-us.ahrq.gov/reports/statbriefs/sb249-appendix.pdf. After comparing diagnoses across the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the ICD-10-CM system, and the Clinical Classification Software (CCS),¹¹ the codes were grouped into the following categories for this Statistical Brief:

- Substance-related diagnoses
 - Alcohol-related disorders
 - Cannabis-related disorders
 - Opioid-related disorders
 - Sedative-related disorders
 - Stimulant-related disorders
 - Miscellaneous substances and addictive disorders (e.g., hallucinogen- and inhalant-related disorders, other psychoactive substance abuse, drug use complicating pregnancy)

¹⁰ Claritas. Claritas Demographic Profile by ZIP Code. <https://claritas360.claritas.com/mybestsegments/>. Accessed January 4, 2019.

¹¹ Agency for Healthcare Research and Quality. Beta HCUP Clinical Classifications Software (CCS) for ICD-10-CM/PCS. Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality. Updated October 2017. www.hcup-us.ahrq.gov/toolssoftware/ccs10/ccs10.jsp. Accessed January 4, 2019.

- Mental disorder-related diagnoses
 - Anxiety disorders
 - Bipolar disorders
 - Depressive disorders
 - Disruptive, impulse-control, and conduct disorders
 - Eating disorders
 - Obsessive-compulsive disorders
 - Personality disorders
 - Schizophrenia and related disorders (e.g., schizophrenia, catatonia, psychotic disorders)
 - Somatic symptom disorders
 - Suicidal ideation or attempt
 - Trauma- and stressor-related disorders (e.g., post-traumatic stress disorder)
 - Miscellaneous mental disorders (e.g., homicidal ideations, unspecified nonpsychotic mental disorders, unspecified childhood emotional disorders, unspecified mental disorders complicating pregnancy)

Note that the definition used in this Statistical Brief may differ from that in other Statistical Briefs and statistics published on HCUP-US and HCUPnet. As a result, rates of substance-related inpatient stays may differ somewhat from similar rates reported elsewhere. In particular, the opioid definition used here includes only codes for initial encounters and not codes for subsequent encounters or sequela. Additionally, substance-related self-harm codes were included in the category for suicidal ideation or attempt instead of the substance-related category. The codes included in this Statistical Brief also differ from those in the CCS categories related to MSUDs available for query in other parts of HCUPnet.

Types of hospitals included in the HCUP National Inpatient Sample

The National Inpatient Sample (NIS) is based on data from community hospitals, which are defined as short-term, non-Federal, general, and other hospitals, excluding hospital units of other institutions (e.g., prisons). The NIS includes obstetrics and gynecology, otolaryngology, orthopedic, cancer, pediatric, public, and academic medical hospitals. Excluded are long-term care facilities such as rehabilitation, psychiatric, and alcoholism and chemical dependency hospitals. Beginning in 2012, long-term acute care hospitals are also excluded. However, if a patient received long-term care, rehabilitation, or treatment for a psychiatric or chemical dependency condition in a community hospital, the discharge record for that stay will be included in the NIS.

Unit of analysis

The unit of analysis is the hospital discharge (i.e., the hospital stay), not a person or patient. This means that a person who is admitted to the hospital multiple times in 1 year will be counted each time as a separate discharge from the hospital.

Population rates

Rates of stays per 100,000 population were calculated using 2016 hospital discharge totals in the numerator and Claritas¹² estimates of the 2016 U.S. population aged 5 years or older in the denominator. Individual patients hospitalized multiple times are counted more than once in the numerator.

$$\text{Population rate of MSUD stays} = \left(\frac{\text{number of MSUD stays among patients aged 5+ years}}{\text{number of U.S. residents aged 5+ years}} \right) \times 100,000$$

¹² Claritas. Claritas Demographic Profile by ZIP Code. <https://claritas360.claritas.com/mybestsegments/>. Accessed January 4, 2019.

Percentage difference

Percentage differences between groups were calculated using the following formula:

$$\text{Percentage difference} = \left(\frac{\text{Group 1 value} - \text{Group 2 value}}{\text{Group 2 value}} \right) \times 100$$

Costs and charges

Total hospital charges were converted to costs using HCUP Cost-to-Charge Ratios based on hospital accounting reports from the Centers for Medicare & Medicaid Services (CMS).¹³ *Costs* reflect the actual expenses incurred in the production of hospital services, such as wages, supplies, and utility costs; *charges* represent the amount a hospital billed for the case. For each hospital, a hospital-wide cost-to-charge ratio is used. Hospital charges reflect the amount the hospital billed for the entire hospital stay and do not include professional (physician) fees. For the purposes of this Statistical Brief, costs are reported to the nearest hundred.

Mean cost per day is calculated as the cost divided by the length of each stay, averaged across all stays.

How HCUP estimates of costs differ from National Health Expenditure Accounts

There are a number of differences between the costs cited in this Statistical Brief and spending as measured in the National Health Expenditure Accounts (NHEA), which are produced annually by CMS.¹⁴ The largest source of difference comes from the HCUP coverage of inpatient treatment only in contrast to the NHEA inclusion of outpatient costs associated with emergency departments and other hospital-based outpatient clinics and departments as well. The outpatient portion of hospitals' activities has been growing steadily and may exceed half of all hospital revenue in recent years. On the basis of the American Hospital Association Annual Survey, 2014 outpatient gross revenues (or charges) were about 46 percent of total hospital gross revenues.¹⁵

Smaller sources of differences come from the inclusion in the NHEA of hospitals that are excluded from HCUP. These include Federal hospitals (Department of Defense, Veterans Administration, Indian Health Services, and Department of Justice [prison] hospitals) as well as psychiatric, substance abuse, and long-term care hospitals. A third source of difference lies in the HCUP reliance on billed charges from hospitals to payers, adjusted to provide estimates of costs using hospital-wide cost-to-charge ratios, in contrast to the NHEA measurement of spending or revenue. HCUP costs estimate the amount of money required to produce hospital services, including expenses for wages, salaries, and benefits paid to staff as well as utilities, maintenance, and other similar expenses required to run a hospital. NHEA spending or revenue measures the amount of income received by the hospital for treatment and other services provided, including payments by insurers, patients, or government programs. The difference between revenues and costs include profit for for-profit hospitals or surpluses for nonprofit hospitals.

Location of patients' residence

Place of residence is based on the urban-rural classification scheme for U.S. counties developed by the National Center for Health Statistics (NCHS). For this Statistical Brief, we collapsed the NCHS categories into either urban or rural according to the following:

Urban:

- Large Central Metropolitan: includes metropolitan areas with 1 million or more residents
- Large Fringe Metropolitan: includes counties of metropolitan areas with 1 million or more residents
- Medium and Small Metropolitan: includes areas with 50,000 to 999,999 residents

¹³ Agency for Healthcare Research and Quality. HCUP Cost-to-Charge Ratio (CCR) Files. Healthcare Cost and Utilization Project (HCUP). 2001–2015. Agency for Healthcare Research and Quality. Updated September 2018. www.hcup-us.ahrq.gov/db/state/costtocharge.jsp. Accessed January 4, 2019.

¹⁴ For additional information about the NHEA, see Centers for Medicare & Medicaid Services (CMS). National Health Expenditure Data. CMS Web site. Updated April 2018. www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/index.html?redirect=/NationalHealthExpendData/. Accessed January 4, 2019.

¹⁵ American Hospital Association. TrendWatch Chartbook, 2016. Table 4.2. Distribution of Inpatient vs. Outpatient Revenues, 1994–2014. www.aha.org/system/files/2018-01/2016-chartbook.pdf. Accessed January 4, 2019.

Rural:

- Micropolitan and Noncore: includes nonmetropolitan counties (i.e., counties with no town greater than 50,000 residents).

Community-level income

Community-level income is based on the median household income of the patient's ZIP Code of residence. Quartiles are defined so that the total U.S. population is evenly distributed. Cut-offs for the quartiles are determined annually using ZIP Code demographic data obtained from Claritas, a vendor that produces population estimates and projections based on data from the U.S. Census Bureau.¹⁶ The value ranges for the income quartiles vary by year. The income quartile is missing for patients who are homeless or foreign.

Expected payer

To make coding uniform across all HCUP data sources, expected payer for the hospital stay combines detailed categories into general groups:

- Expected payer for patients aged less than 65 years:
 - Medicare: includes fee-for-service and managed care Medicare
 - Medicaid: includes fee-for-service and managed care Medicaid
 - Private Insurance: includes commercial nongovernmental payers, regardless of the type of plan (e.g., private health maintenance organizations [HMOs], preferred provider organizations [PPOs])
 - Self-pay/no charge: includes self-pay, no charge, charity, Hill Burton Free care, research (e.g., clinical trial or donor), refusal to pay, and no payment
 - Other payers: includes other Federal and local government programs (e.g., TRICARE, CHAMPVA, Indian Health Service, Black Lung, Title V) and Workers' Compensation
- Expected payer for patients aged 65 years old or older:
 - Medicare: includes fee-for-service and managed care Medicare
 - Non-Medicare: includes all other expected payer categories, as described above (i.e., Medicaid, private insurance, self-pay/no charge, other payers).

Hospital stays billed to the State Children's Health Insurance Program (SCHIP) may be classified as Medicaid, Private Insurance, or Other, depending on the structure of the State program. Because most State data do not identify SCHIP as an expected payer specifically, it is not possible to present this information separately.

Region

Region is one of the four regions defined by the U.S. Census Bureau:

- Northeast: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Pennsylvania
- Midwest: Ohio, Indiana, Illinois, Michigan, Wisconsin, Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, and Kansas
- South: Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida, Kentucky, Tennessee, Alabama, Mississippi, Arkansas, Louisiana, Oklahoma, and Texas
- West: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada, Washington, Oregon, California, Alaska, and Hawaii

¹⁶ Claritas. Claritas Demographic Profile by ZIP Code. <https://claritas360.claritas.com/mybestsegments/>. Accessed January 4, 2019.

Division

Division corresponds to the location of the hospital and is one of the nine divisions defined by the U.S. Census Bureau:

- New England: Maine, New Hampshire, Vermont, Massachusetts, Rhode Island, Connecticut
- Middle Atlantic: New York, New Jersey, Pennsylvania
- East North Central: Ohio, Indiana, Illinois, Michigan, Wisconsin
- West North Central: Minnesota, Iowa, Missouri, North Dakota, South Dakota, Nebraska, Kansas
- South Atlantic: Delaware, Maryland, District of Columbia, Virginia, West Virginia, North Carolina, South Carolina, Georgia, Florida
- East South Central: Kentucky, Tennessee, Alabama, Mississippi
- West South Central: Arkansas, Louisiana, Oklahoma, Texas
- Mountain: Montana, Idaho, Wyoming, Colorado, New Mexico, Arizona, Utah, Nevada
- Pacific: Washington, Oregon, California, Alaska, Hawaii

Admission source or point of origin

Admission source (now known as the patient's point of origin) indicates where the patient was located prior to admission to the hospital. Emergency admission indicates that the patient was admitted to the hospital through the emergency department.

Discharge status

Discharge status reflects the disposition of the patient at discharge from the hospital and includes the following five categories: routine (to home) or home health care; transfer to another short-term hospital; other transfers (including skilled nursing facility, intermediate care, and another type of facility such as a nursing home); died in the hospital; or other (including against medical advice and discharged alive, destination unknown).

About HCUP

The Healthcare Cost and Utilization Project (HCUP, pronounced "H-Cup") is a family of health care databases and related software tools and products developed through a Federal-State-Industry partnership and sponsored by the Agency for Healthcare Research and Quality (AHRQ). HCUP databases bring together the data collection efforts of State data organizations, hospital associations, and private data organizations (HCUP Partners) and the Federal government to create a national information resource of encounter-level health care data. HCUP includes the largest collection of longitudinal hospital care data in the United States, with all-payer, encounter-level information beginning in 1988. These databases enable research on a broad range of health policy issues, including cost and quality of health services, medical practice patterns, access to health care programs, and outcomes of treatments at the national, State, and local market levels.

HCUP would not be possible without the contributions of the following data collection Partners from across the United States:

Alaska Department of Health and Social Services
Alaska State Hospital and Nursing Home Association
Arizona Department of Health Services
Arkansas Department of Health
California Office of Statewide Health Planning and Development
Colorado Hospital Association
Connecticut Hospital Association
Delaware Division of Public Health
District of Columbia Hospital Association
Florida Agency for Health Care Administration
Georgia Hospital Association
Hawaii Health Information Corporation
Illinois Department of Public Health
Indiana Hospital Association

Iowa Hospital Association
Kansas Hospital Association
Kentucky Cabinet for Health and Family Services
Louisiana Department of Health
Maine Health Data Organization
Maryland Health Services Cost Review Commission
Massachusetts Center for Health Information and Analysis
Michigan Health & Hospital Association
Minnesota Hospital Association
Mississippi State Department of Health
Missouri Hospital Industry Data Institute
Montana Hospital Association
Nebraska Hospital Association
Nevada Department of Health and Human Services
New Hampshire Department of Health & Human Services
New Jersey Department of Health
New Mexico Department of Health
New York State Department of Health
North Carolina Department of Health and Human Services
North Dakota (data provided by the Minnesota Hospital Association)
Ohio Hospital Association
Oklahoma State Department of Health
Oregon Association of Hospitals and Health Systems
Oregon Office of Health Analytics
Pennsylvania Health Care Cost Containment Council
Rhode Island Department of Health
South Carolina Revenue and Fiscal Affairs Office
South Dakota Association of Healthcare Organizations
Tennessee Hospital Association
Texas Department of State Health Services
Utah Department of Health
Vermont Association of Hospitals and Health Systems
Virginia Health Information
Washington State Department of Health
West Virginia Department of Health and Human Resources, West Virginia Health Care Authority
Wisconsin Department of Health Services
Wyoming Hospital Association

About the NIS

The HCUP National Inpatient Sample (NIS) is a nationwide database of hospital inpatient stays. The NIS is nationally representative of all community hospitals (i.e., short-term, non-Federal, nonrehabilitation hospitals). The NIS includes all payers. It is drawn from a sampling frame that contains hospitals comprising more than 95 percent of all discharges in the United States. The vast size of the NIS allows the study of topics at the national and regional levels for specific subgroups of patients. In addition, NIS data are standardized across years to facilitate ease of use. Over time, the sampling frame for the NIS has changed; thus, the number of States contributing to the NIS varies from year to year. The NIS is intended for national estimates only; no State-level estimates can be produced. The unweighted sample size for the 2016 NIS is 7,135,090 (weighted, this represents 35,675,421 inpatient stays).

For More Information

For other information on mental and substance use disorders, refer to the HCUP Statistical Briefs located at www.hcup-us.ahrq.gov/reports/statbriefs/sb_mhsa.jsp.

For additional HCUP statistics, visit:

- HCUP Fast Stats at www.hcup-us.ahrq.gov/faststats/landing.jsp for easy access to the latest HCUP-based statistics for health care information topics
- HCUPnet, HCUP's interactive query system, at www.hcupnet.ahrq.gov/

For more information about HCUP, visit www.hcup-us.ahrq.gov/.

For a detailed description of HCUP and more information on the design of the National Inpatient Sample (NIS), please refer to the following database documentation:

Agency for Healthcare Research and Quality. Overview of the National (Nationwide) Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality. Updated August 2018. www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed January 4, 2019.

Suggested Citation

Owens PL (AHRQ), Fingar KR (IBM Watson Health), McDermott KW (IBM Watson Health), Muhuri PK (AHRQ), Heslin KC (AHRQ). Inpatient Stays Involving Mental and Substance Use Disorders, 2016. HCUP Statistical Brief #249. March 2019. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/reports/statbriefs/sb249-Mental-Substance-Use-Disorder-Hospital-Stays-2016.pdf

Acknowledgments

The authors would like to acknowledge the contributions of Minya Sheng of IBM Watson Health.

* * *

AHRQ welcomes questions and comments from readers of this publication who are interested in obtaining more information about access, cost, use, financing, and quality of health care in the United States. We also invite you to tell us how you are using this Statistical Brief and other HCUP data and tools, and to share suggestions on how HCUP products might be enhanced to further meet your needs. Please e-mail us at hcup@ahrq.gov or send a letter to the address below:

Joel Cohen, Ph.D., Director
Center for Financing, Access and Cost Trends
Agency for Healthcare Research and Quality
5600 Fishers Lane
Rockville, MD 20857

This Statistical Brief was posted online on March 26, 2019.

Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project, Statistical Brief #249: Inpatient Stays Involving Mental and Substance Use Disorders, 2016 (Owens PL, Fingar KR, McDermott KW, Muhuri PK, Heslin KC)

APPENDIX B: ICD-10-CM codes defining mental and substance use disorders, by category

Code	Mental or substance use disorder
Substance-related diagnoses	
Alcohol-related disorders	
F1010	Alcohol abuse, uncomplicated
F10120	Alcohol abuse with intoxication, uncomplicated
F10121	Alcohol abuse with intoxication delirium
F10129	Alcohol abuse with intoxication, unspecified
F1014	Alcohol abuse with alcohol-induced mood disorder
F10150	Alcohol abuse with alcohol-induced psychotic disorder with delusions
F10151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations
F10159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified
F10180	Alcohol abuse with alcohol-induced anxiety disorder
F10181	Alcohol abuse with alcohol-induced sexual dysfunction
F10182	Alcohol abuse with alcohol-induced sleep disorder
F10188	Alcohol abuse with other alcohol-induced disorder
F1019	Alcohol abuse with unspecified alcohol-induced disorder
F1020	Alcohol dependence, uncomplicated
F10220	Alcohol dependence with intoxication, uncomplicated
F10221	Alcohol dependence with intoxication delirium
F10229	Alcohol dependence with intoxication, unspecified
F10230	Alcohol dependence with withdrawal, uncomplicated
F10231	Alcohol dependence with withdrawal delirium
F10232	Alcohol dependence with withdrawal with perceptual disturbance
F10239	Alcohol dependence with withdrawal, unspecified
F1024	Alcohol dependence with alcohol-induced mood disorder
F10250	Alcohol dependence with alcohol-induced psychotic disorder with delusions
F10251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations
F10259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified
F1026	Alcohol dependence with alcohol-induced persisting amnesic disorder
F1027	Alcohol dependence with alcohol-induced persisting dementia
F10280	Alcohol dependence with alcohol-induced anxiety disorder
F10281	Alcohol dependence with alcohol-induced sexual dysfunction
F10282	Alcohol dependence with alcohol-induced sleep disorder
F10288	Alcohol dependence with other alcohol-induced disorder
F1029	Alcohol dependence with unspecified alcohol-induced disorder
F10920	Alcohol use, unspecified with intoxication, uncomplicated
F10921	Alcohol use, unspecified with intoxication delirium
F10929	Alcohol use, unspecified with intoxication, unspecified
F1094	Alcohol use, unspecified with alcohol-induced mood disorder
F10950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions
F10951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations
F10959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified
F1096	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder

Code	Mental or substance use disorder
F1097	Alcohol use, unspecified with alcohol-induced persisting dementia
F10980	Alcohol use, unspecified with alcohol-induced anxiety disorder
F10981	Alcohol use, unspecified with alcohol-induced sexual dysfunction
F10982	Alcohol use, unspecified with alcohol-induced sleep disorder
F10988	Alcohol use, unspecified with other alcohol-induced disorder
F1099	Alcohol use, unspecified with unspecified alcohol-induced disorder
G621	Alcoholic polyneuropathy
I426	Alcoholic cardiomyopathy
K2920	Alcoholic gastritis without bleeding
K2921	Alcoholic gastritis with bleeding
K700	Alcoholic fatty liver
K7010	Alcoholic hepatitis without ascites
K7011	Alcoholic hepatitis with ascites
K702	Alcoholic fibrosis and sclerosis of liver
K7030	Alcoholic cirrhosis of liver without ascites
K7031	Alcoholic cirrhosis of liver with ascites
K7040	Alcoholic hepatic failure without coma
K7041	Alcoholic hepatic failure with coma
K709	Alcoholic liver disease, unspecified
O354XX0	Maternal care for (suspected) damage to fetus from alcohol, not applicable or unspecified
O354XX1	Maternal care for (suspected) damage to fetus from alcohol, fetus 1
O354XX2	Maternal care for (suspected) damage to fetus from alcohol, fetus 2
O354XX3	Maternal care for (suspected) damage to fetus from alcohol, fetus 3
O354XX4	Maternal care for (suspected) damage to fetus from alcohol, fetus 4
O354XX5	Maternal care for (suspected) damage to fetus from alcohol, fetus 5
O354XX9	Maternal care for (suspected) damage to fetus from alcohol, other fetus
O99310	Alcohol use complicating pregnancy, unspecified trimester
O99311	Alcohol use complicating pregnancy, first trimester
O99312	Alcohol use complicating pregnancy, second trimester
O99313	Alcohol use complicating pregnancy, third trimester
O99314	Alcohol use complicating childbirth
O99315	Alcohol use complicating the puerperium
Cannabis-related disorders	
F1210	Cannabis abuse, uncomplicated
F12120	Cannabis abuse with intoxication, uncomplicated
F12121	Cannabis abuse with intoxication delirium
F12122	Cannabis abuse with intoxication with perceptual disturbance
F12129	Cannabis abuse with intoxication, unspecified
F12150	Cannabis abuse with psychotic disorder with delusions
F12151	Cannabis abuse with psychotic disorder with hallucinations
F12159	Cannabis abuse with psychotic disorder, unspecified
F12180	Cannabis abuse with cannabis-induced anxiety disorder
F12188	Cannabis abuse with other cannabis-induced disorder
F1219	Cannabis abuse with unspecified cannabis-induced disorder
F1220	Cannabis dependence, uncomplicated
F12220	Cannabis dependence with intoxication, uncomplicated

Code	Mental or substance use disorder
F12221	Cannabis dependence with intoxication delirium
F12222	Cannabis dependence with intoxication with perceptual disturbance
F12229	Cannabis dependence with intoxication, unspecified
F12250	Cannabis dependence with psychotic disorder with delusions
F12251	Cannabis dependence with psychotic disorder with hallucinations
F12259	Cannabis dependence with psychotic disorder, unspecified
F12280	Cannabis dependence with cannabis-induced anxiety disorder
F12288	Cannabis dependence with other cannabis-induced disorder
F1229	Cannabis dependence with unspecified cannabis-induced disorder
F1290	Cannabis use, unspecified, uncomplicated
F12920	Cannabis use, unspecified with intoxication, uncomplicated
F12921	Cannabis use, unspecified with intoxication delirium
F12922	Cannabis use, unspecified with intoxication with perceptual disturbance
F12929	Cannabis use, unspecified with intoxication, unspecified
F12950	Cannabis use, unspecified with psychotic disorder with delusions
F12951	Cannabis use, unspecified with psychotic disorder with hallucinations
F12959	Cannabis use, unspecified with psychotic disorder, unspecified
F12980	Cannabis use, unspecified with anxiety disorder
F12988	Cannabis use, unspecified with other cannabis-induced disorder
F1299	Cannabis use, unspecified with unspecified cannabis-induced disorder
T407X1A	Poisoning by cannabis (derivatives), accidental, initial encounter
T407X3A	Poisoning by cannabis (derivatives), assault, initial encounter
T407X4A	Poisoning by cannabis (derivatives), undetermined, initial encounter
T407X5A	Adverse effect of cannabis (derivatives), initial encounter
Opioid-related disorders	
F1110	Opioid abuse, uncomplicated
F11120	Opioid abuse with intoxication, uncomplicated
F11121	Opioid abuse with intoxication delirium
F11122	Opioid abuse with intoxication with perceptual disturbance
F11129	Opioid abuse with intoxication, unspecified
F1114	Opioid abuse with opioid-induced mood disorder
F11150	Opioid abuse with opioid-induced psychotic disorder with delusions
F11151	Opioid abuse with opioid-induced psychotic disorder with hallucinations
F11159	Opioid abuse with opioid-induced psychotic disorder, unspecified
F11181	Opioid abuse with opioid-induced sexual dysfunction
F11182	Opioid abuse with opioid-induced sleep disorder
F11188	Opioid abuse with other opioid-induced disorder
F1119	Opioid abuse with unspecified opioid-induced disorder
F1120	Opioid dependence, uncomplicated
F11220	Opioid dependence with intoxication, uncomplicated
F11221	Opioid dependence with intoxication delirium
F11222	Opioid dependence with intoxication with perceptual disturbance
F11229	Opioid dependence with intoxication, unspecified
F1123	Opioid dependence with withdrawal
F1124	Opioid dependence with opioid-induced mood disorder
F11250	Opioid dependence with opioid-induced psychotic disorder with delusions
F11251	Opioid dependence with opioid-induced psychotic disorder with hallucinations

Code	Mental or substance use disorder
F11259	Opioid dependence with opioid-induced psychotic disorder, unspecified
F11281	Opioid dependence with opioid-induced sexual dysfunction
F11282	Opioid dependence with opioid-induced sleep disorder
F11288	Opioid dependence with other opioid-induced disorder
F1129	Opioid dependence with unspecified opioid-induced disorder
F1190	Opioid use, unspecified, uncomplicated
F11920	Opioid use, unspecified with intoxication, uncomplicated
F11921	Opioid use, unspecified with intoxication delirium
F11922	Opioid use, unspecified with intoxication with perceptual disturbance
F11929	Opioid use, unspecified with intoxication, unspecified
F1193	Opioid use, unspecified with withdrawal
F1194	Opioid use, unspecified with opioid-induced mood disorder
F11950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions
F11951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations
F11959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified
F11981	Opioid use, unspecified with opioid-induced sexual dysfunction
F11982	Opioid use, unspecified with opioid-induced sleep disorder
F11988	Opioid use, unspecified with other opioid-induced disorder
F1199	Opioid use, unspecified with unspecified opioid-induced disorder
T400X1A	Poisoning by opium, accidental (unintentional), initial encounter
T400X3A	Poisoning by opium, assault, initial encounter
T400X4A	Poisoning by opium, undetermined, initial encounter
T400X5A	Adverse effect of opium, initial encounter
T401X1A	Poisoning by heroin, accidental (unintentional), initial encounter
T401X3A	Poisoning by heroin, assault, initial encounter
T401X4A	Poisoning by heroin, undetermined, initial encounter
T402X1A	Poisoning by other opioids, accidental (unintentional), initial encounter
T402X3A	Poisoning by other opioids, assault, initial encounter
T402X4A	Poisoning by other opioids, undetermined, initial encounter
T402X5A	Adverse effect of other opioids, initial encounter
T403X1A	Poisoning by methadone, accidental (unintentional), initial encounter
T403X3A	Poisoning by methadone, assault, initial encounter
T403X4A	Poisoning by methadone, undetermined, initial encounter
T403X5A	Adverse effect of methadone, initial encounter
T404X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter
T404X3A	Poisoning by other synthetic narcotics, assault, initial encounter
T404X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter
T404X5A	Adverse effect of other synthetic narcotics, initial encounter
T40601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter
T40603A	Poisoning by unspecified narcotics, assault, initial encounter
T40604A	Poisoning by unspecified narcotics, undetermined, initial encounter
T40605A	Adverse effect of unspecified narcotics, initial encounter
T40691A	Poisoning by other narcotics, accidental (unintentional), initial encounter
T40693A	Poisoning by other narcotics, assault, initial encounter
T40694A	Poisoning by other narcotics, undetermined, initial encounter
T40695A	Adverse effect of other narcotics, initial encounter
Sedative-related disorders	

Code	Mental or substance use disorder
F1310	Sedative, hypnotic or anxiolytic abuse, uncomplicated
F13120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated
F13121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium
F13129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified
F1314	Sedative, hypnotic or anxiolytic abuse with mood disorder
F13150	Sedative, hypnotic or anxiolytic abuse with psychotic disorder with delusions
F13151	Sedative, hypnotic or anxiolytic abuse with psychotic disorder with hallucinations
F13159	Sedative, hypnotic or anxiolytic abuse with psychotic disorder, unspecified
F13180	Sedative, hypnotic or anxiolytic abuse with anxiety disorder
F13181	Sedative, hypnotic or anxiolytic abuse with sexual dysfunction
F13182	Sedative, hypnotic or anxiolytic abuse with sleep disorder
F13188	Sedative, hypnotic or anxiolytic abuse with other disorder
F1319	Sedative, hypnotic or anxiolytic abuse with unspecified disorder
F1320	Sedative, hypnotic or anxiolytic dependence, uncomplicated
F13220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated
F13221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium
F13229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified
F13230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated
F13231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium
F13232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturb
F13239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified
F1324	Sedative, hypnotic or anxiolytic dependence with mood disorder
F13250	Sedative, hypnotic or anxiolytic dependence with psychotic disorder with delusions
F13251	Sedative, hypnotic or anxiolytic dependence with psychotic disorder with hallucinations
F13259	Sedative, hypnotic or anxiolytic dependence with psychotic disorder, unspecified
F1326	Sedative, hypnotic or anxiolytic dependence with persisting amnestic disorder
F1327	Sedative, hypnotic or anxiolytic dependence with persisting dementia
F13280	Sedative, hypnotic or anxiolytic dependence with anxiety disorder
F13281	Sedative, hypnotic or anxiolytic dependence with sexual dysfunction
F13282	Sedative, hypnotic or anxiolytic dependence with sleep disorder
F13288	Sedative, hypnotic or anxiolytic dependence with other disorder
F1329	Sedative, hypnotic or anxiolytic dependence with unspecified disorder
F1390	Sedative, hypnotic or anxiolytic use, unspecified, uncomplicated
F13920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated
F13921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium
F13929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified
F13930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated
F13931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium
F13932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbance
F13939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified
F1394	Sedative, hypnotic or anxiolytic use, unspecified with mood disorder
F13950	Sedative, hypnotic or anxiolytic use, unspecified with psychotic disorder with delusions
F13951	Sedative, hypnotic or anxiolytic use, unspecified with psychotic disorder with hallucinations
F13959	Sedative, hypnotic or anxiolytic use, unspecified with psychotic disorder, unspecified
F1396	Sedative, hypnotic or anxiolytic use, unspecified with persisting amnestic disorder

Code	Mental or substance use disorder
F1397	Sedative, hypnotic or anxiolytic use, unspecified with persisting dementia
F13980	Sedative, hypnotic or anxiolytic use, unspecified with anxiety disorder
F13981	Sedative, hypnotic or anxiolytic use, unspecified with sexual dysfunction
F13982	Sedative, hypnotic or anxiolytic use, unspecified with sleep disorder
F13988	Sedative, hypnotic or anxiolytic use, unspecified with other disorder
F1399	Sedative, hypnotic or anxiolytic use, unspecified with unspecified disorder
Stimulant-related disorders	
F1410	Cocaine abuse, uncomplicated
F14120	Cocaine abuse with intoxication, uncomplicated
F14121	Cocaine abuse with intoxication with delirium
F14122	Cocaine abuse with intoxication with perceptual disturbance
F14129	Cocaine abuse with intoxication, unspecified
F1414	Cocaine abuse with cocaine-induced mood disorder
F14150	Cocaine abuse with cocaine-induced psychotic disorder with delusions
F14151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations
F14159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified
F14180	Cocaine abuse with cocaine-induced anxiety disorder
F14181	Cocaine abuse with cocaine-induced sexual dysfunction
F14182	Cocaine abuse with cocaine-induced sleep disorder
F14188	Cocaine abuse with other cocaine-induced disorder
F1419	Cocaine abuse with unspecified cocaine-induced disorder
F1420	Cocaine dependence, uncomplicated
F14220	Cocaine dependence with intoxication, uncomplicated
F14221	Cocaine dependence with intoxication delirium
F14222	Cocaine dependence with intoxication with perceptual disturbance
F14229	Cocaine dependence with intoxication, unspecified
F1423	Cocaine dependence with withdrawal
F1424	Cocaine dependence with cocaine-induced mood disorder
F14250	Cocaine dependence with cocaine-induced psychotic disorder with delusions
F14251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations
F14259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified
F14280	Cocaine dependence with cocaine-induced anxiety disorder
F14281	Cocaine dependence with cocaine-induced sexual dysfunction
F14282	Cocaine dependence with cocaine-induced sleep disorder
F14288	Cocaine dependence with other cocaine-induced disorder
F1429	Cocaine dependence with unspecified cocaine-induced disorder
F1490	Cocaine use, unspecified, uncomplicated
F14920	Cocaine use, unspecified with intoxication, uncomplicated
F14921	Cocaine use, unspecified with intoxication delirium
F14922	Cocaine use, unspecified with intoxication with perceptual disturbance
F14929	Cocaine use, unspecified with intoxication, unspecified
F1494	Cocaine use, unspecified with cocaine-induced mood disorder
F14950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions
F14951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations
F14959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified
F14980	Cocaine use, unspecified with cocaine-induced anxiety disorder
F14981	Cocaine use, unspecified with cocaine-induced sexual dysfunction

Code	Mental or substance use disorder
F14982	Cocaine use, unspecified with cocaine-induced sleep disorder
F14988	Cocaine use, unspecified with other cocaine-induced disorder
F1499	Cocaine use, unspecified with unspecified cocaine-induced disorder
F1510	Other stimulant abuse, uncomplicated
F15120	Other stimulant abuse with intoxication, uncomplicated
F15121	Other stimulant abuse with intoxication delirium
F15122	Other stimulant abuse with intoxication with perceptual disturbance
F15129	Other stimulant abuse with intoxication, unspecified
F1514	Other stimulant abuse with stimulant-induced mood disorder
F15150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions
F15151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations
F15159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified
F15180	Other stimulant abuse with stimulant-induced anxiety disorder
F15181	Other stimulant abuse with stimulant-induced sexual dysfunction
F15182	Other stimulant abuse with stimulant-induced sleep disorder
F15188	Other stimulant abuse with other stimulant-induced disorder
F1519	Other stimulant abuse with unspecified stimulant-induced disorder
F1520	Other stimulant dependence, uncomplicated
F15220	Other stimulant dependence with intoxication, uncomplicated
F15221	Other stimulant dependence with intoxication delirium
F15222	Other stimulant dependence with intoxication with perceptual disturbance
F15229	Other stimulant dependence with intoxication, unspecified
F1523	Other stimulant dependence with withdrawal
F1524	Other stimulant dependence with stimulant-induced mood disorder
F15250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions
F15251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations
F15259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified
F15280	Other stimulant dependence with stimulant-induced anxiety disorder
F15281	Other stimulant dependence with stimulant-induced sexual dysfunction
F15282	Other stimulant dependence with stimulant-induced sleep disorder
F15288	Other stimulant dependence with other stimulant-induced disorder
F1529	Other stimulant dependence with unspecified stimulant-induced disorder
F1590	Other stimulant use, unspecified, uncomplicated
F15920	Other stimulant use, unspecified with intoxication, uncomplicated
F15921	Other stimulant use, unspecified with intoxication delirium
F15922	Other stimulant use, unspecified with intoxication with perceptual disturbance
F15929	Other stimulant use, unspecified with intoxication, unspecified
F1593	Other stimulant use, unspecified with withdrawal
F1594	Other stimulant use, unspecified with stimulant-induced mood disorder
F15950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions
F15951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations
F15959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified
F15980	Other stimulant use, unspecified with stimulant-induced anxiety disorder
F15981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction
F15982	Other stimulant use, unspecified with stimulant-induced sleep disorder

Code	Mental or substance use disorder
F15988	Other stimulant use, unspecified with other stimulant-induced disorder
F1599	Other stimulant use, unspecified with unspecified stimulant-induced disorder
T405X1A	Poisoning by cocaine, accidental (unintentional), initial encounter
T405X3A	Poisoning by cocaine, assault, initial encounter
T405X4A	Poisoning by cocaine, undetermined, initial encounter
T405X5A	Adverse effect of cocaine, initial encounter
T43601A	Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter
T43603A	Poisoning by unspecified psychostimulants, assault, initial encounter
T43604A	Poisoning by unspecified psychostimulants, undetermined, initial encounter
T43605A	Adverse effect of unspecified psychostimulants, initial encounter
T43621A	Poisoning by amphetamines, accidental (unintentional), initial encounter
T43623A	Poisoning by amphetamines, assault, initial encounter
T43624A	Poisoning by amphetamines, undetermined, initial encounter
T43625A	Adverse effect of amphetamines, initial encounter
T43631A	Poisoning by methylphenidate, accidental (unintentional), initial encounter
T43633A	Poisoning by methylphenidate, assault, initial encounter
T43634A	Poisoning by methylphenidate, undetermined, initial encounter
T43635A	Adverse effect of methylphenidate, initial encounter
T43691A	Poisoning by other psychostimulants, accidental (unintentional), initial encounter
T43693A	Poisoning by other psychostimulants, assault, initial encounter
T43694A	Poisoning by other psychostimulants, undetermined, initial encounter
T43695A	Adverse effect of other psychostimulants, initial encounter
Miscellaneous substances and addictive disorders	
F1610	Hallucinogen abuse, uncomplicated
F16120	Hallucinogen abuse with intoxication, uncomplicated
F16121	Hallucinogen abuse with intoxication with delirium
F16122	Hallucinogen abuse with intoxication with perceptual disturbance
F16129	Hallucinogen abuse with intoxication, unspecified
F1614	Hallucinogen abuse with hallucinogen-induced mood disorder
F16150	Hallucinogen abuse with psychotic disorder with delusions
F16151	Hallucinogen abuse with psychotic disorder with hallucinations
F16159	Hallucinogen abuse with psychotic disorder, unspecified
F16180	Hallucinogen abuse with hallucinogen-induced anxiety disorder
F16183	Hallucinogen abuse with hallucinogen persisting perception disorder
F16188	Hallucinogen abuse with other hallucinogen-induced disorder
F1619	Hallucinogen abuse with unspecified hallucinogen-induced disorder
F1620	Hallucinogen dependence, uncomplicated
F16220	Hallucinogen dependence with intoxication, uncomplicated
F16221	Hallucinogen dependence with intoxication with delirium
F16229	Hallucinogen dependence with intoxication, unspecified
F1624	Hallucinogen dependence with hallucinogen-induced mood disorder
F16250	Hallucinogen dependence with psychotic disorder with delusions
F16251	Hallucinogen dependence with psychotic disorder with hallucinations
F16259	Hallucinogen dependence with psychotic disorder, unspecified
F16280	Hallucinogen dependence with anxiety disorder
F16283	Hallucinogen dependence with hallucinogen persisting perception disorder
F16288	Hallucinogen dependence with other hallucinogen-induced disorder

Code	Mental or substance use disorder
F1629	Hallucinogen dependence with unspecified hallucinogen-induced disorder
F1690	Hallucinogen use, unspecified, uncomplicated
F16920	Hallucinogen use, unspecified with intoxication, uncomplicated
F16921	Hallucinogen use, unspecified with intoxication with delirium
F16929	Hallucinogen use, unspecified with intoxication, unspecified
F1694	Hallucinogen use, unspecified with hallucinogen-induced mood disorder
F16950	Hallucinogen use, unspecified with psychotic disorder with delusions
F16951	Hallucinogen use, unspecified with psychotic disorder with hallucinations
F16959	Hallucinogen use, unspecified with psychotic disorder, unspecified
F16980	Hallucinogen use, unspecified with anxiety disorder
F16983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder
F16988	Hallucinogen use, unspecified with other hallucinogen-induced disorder
F1699	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder
F1810	Inhalant abuse, uncomplicated
F18120	Inhalant abuse with intoxication, uncomplicated
F18121	Inhalant abuse with intoxication delirium
F18129	Inhalant abuse with intoxication, unspecified
F1814	Inhalant abuse with inhalant-induced mood disorder
F18150	Inhalant abuse with inhalant-induced psychotic disorder with delusions
F18151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations
F18159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified
F1817	Inhalant abuse with inhalant-induced dementia
F18180	Inhalant abuse with inhalant-induced anxiety disorder
F18188	Inhalant abuse with other inhalant-induced disorder
F1819	Inhalant abuse with unspecified inhalant-induced disorder
F1820	Inhalant dependence, uncomplicated
F18220	Inhalant dependence with intoxication, uncomplicated
F18221	Inhalant dependence with intoxication delirium
F18229	Inhalant dependence with intoxication, unspecified
F1824	Inhalant dependence with inhalant-induced mood disorder
F18250	Inhalant dependence with inhalant-induced psychotic disorder with delusions
F18251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations
F18259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified
F1827	Inhalant dependence with inhalant-induced dementia
F18280	Inhalant dependence with inhalant-induced anxiety disorder
F18288	Inhalant dependence with other inhalant-induced disorder
F1829	Inhalant dependence with unspecified inhalant-induced disorder
F1890	Inhalant use, unspecified, uncomplicated
F18920	Inhalant use, unspecified with intoxication, uncomplicated
F18921	Inhalant use, unspecified with intoxication with delirium
F18929	Inhalant use, unspecified with intoxication, unspecified
F1894	Inhalant use, unspecified with inhalant-induced mood disorder
F18950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions
F18951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations
F18959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified
F1897	Inhalant use, unspecified with inhalant-induced persisting dementia
F18980	Inhalant use, unspecified with inhalant-induced anxiety disorder

Code	Mental or substance use disorder
F18988	Inhalant use, unspecified with other inhalant-induced disorder
F1899	Inhalant use, unspecified with unspecified inhalant-induced disorder
F1910	Other psychoactive substance abuse, uncomplicated
F19120	Other psychoactive substance abuse with intoxication, uncomplicated
F19121	Other psychoactive substance abuse with intoxication delirium
F19122	Other psychoactive substance abuse with intoxication with perceptual disturb
F19129	Other psychoactive substance abuse with intoxication, unspecified
F1914	Other psychoactive substance abuse with mood disorder
F19150	Other psychoactive substance abuse with psychotic disorder with delusions
F19151	Other psychoactive substance abuse with psychotic disorder with hallucinations
F19159	Other psychoactive substance abuse with psychotic disorder, unspecified
F1916	Other psychoactive substance abuse with persist amnestic disorder
F1917	Other psychoactive substance abuse with persisting dementia
F19180	Other psychoactive substance abuse with anxiety disorder
F19181	Other psychoactive substance abuse with sexual dysfunction
F19182	Other psychoactive substance abuse with sleep disorder
F19188	Other psychoactive substance abuse with other disorder
F1919	Other psychoactive substance abuse with unspecified disorder
F1920	Other psychoactive substance dependence, uncomplicated
F19220	Other psychoactive substance dependence with intoxication, uncomplicated
F19221	Other psychoactive substance dependence with intoxication delirium
F19222	Other psychoactive substance dependence with intoxication with perceptual disturbance
F19229	Other psychoactive substance dependence with intoxication, unspecified
F19230	Other psychoactive substance dependence with withdrawal, uncomplicated
F19231	Other psychoactive substance dependence with withdrawal delirium
F19232	Other psychoactive substance dependence with withdrawal with perceptual disturbance
F19239	Other psychoactive substance dependence with withdrawal, unspecified
F1924	Other psychoactive substance dependence with mood disorder
F19250	Other psychoactive substance dependence with psychotic disorder with delusions
F19251	Other psychoactive substance dependence with psychotic disorder with hallucinations
F19259	Other psychoactive substance dependence with psychotic disorder, unspecified
F1926	Other psychoactive substance dependence with persisting amnestic disorder
F1927	Other psychoactive substance dependence with persisting dementia
F19280	Other psychoactive substance dependence with anxiety disorder
F19281	Other psychoactive substance dependence with sexual dysfunction
F19282	Other psychoactive substance dependence with sleep disorder
F19288	Other psychoactive substance dependence with other disorder
F1929	Other psychoactive substance dependence with unspecified disorder
F1990	Other psychoactive substance use, unspecified, uncomplicated
F19920	Other psychoactive substance use, unspecified with intoxication, uncomplicated
F19921	Other psychoactive substance use, unspecified with intoxication with delirium
F19922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance
F19929	Other psychoactive substance use, unspecified with intoxication, unspecified
F19930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated
F19931	Other psychoactive substance use, unspecified with withdrawal delirium

Code	Mental or substance use disorder
F19932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance
F19939	Other psychoactive substance use, unspecified with withdrawal, unspecified
F1994	Other psychoactive substance use, unspecified with mood disorder
F19950	Other psychoactive substance use, unspecified with psychotic disorder with delusions
F19951	Other psychoactive substance use, unspecified with psychotic disorder with hallucinations
F19959	Other psychoactive substance use, unspecified with psychotic disorder, unspecified
F1996	Other psychoactive substance use, unspecified with persisting amnestic disorder
F1997	Other psychoactive substance use, unspecified with persisting dementia
F19980	Other psychoactive substance use, unspecified with anxiety disorder
F19981	Other psychoactive substance use, unspecified with sexual dysfunction
F19982	Other psychoactive substance use, unspecified with sleep disorder
F19988	Other psychoactive substance use, unspecified with other disorder
F1999	Other psychoactive substance use, unspecified with unspecified disorder
F550	Abuse of antacids
F551	Abuse of herbal or folk remedies
F552	Abuse of laxatives
F553	Abuse of steroids or hormones
F554	Abuse of vitamins
F558	Abuse of other non-psychoactive substances
F630	Pathological gambling
O355XX0	Maternal care for (suspected) damage to fetus by drugs, unspecified
O355XX1	Maternal care for damage to fetus by drugs, fetus 1
O355XX2	Maternal care for damage to fetus by drugs, fetus 2
O355XX3	Maternal care for damage to fetus by drugs, fetus 3
O355XX4	Maternal care for damage to fetus by drugs, fetus 4
O355XX5	Maternal care for damage to fetus by drugs, fetus 5
O355XX9	Maternal care for (suspected) damage to fetus by drugs, other
O99320	Drug use complicating pregnancy, unspecified trimester
O99321	Drug use complicating pregnancy, first trimester
O99322	Drug use complicating pregnancy, second trimester
O99323	Drug use complicating pregnancy, third trimester
O99324	Drug use complicating childbirth
O99325	Drug use complicating the puerperium
T408X1A	Poisoning by lysergide, accidental (unintentional), initial encounter
T408X3A	Poisoning by lysergide [LSD], assault, initial encounter
T408X4A	Poisoning by lysergide, undetermined, initial encounter
T40901A	Poisoning by unspecified psychodysleptics, accidental, initial encounter
T40903A	Poisoning by unspecified psychodysleptics, assault, initial encounter
T40904A	Poisoning by unspecified psychodysleptics, undetermined, initial encounter
T40905A	Adverse effect of unspecified psychodysleptics, initial encounter
T40991A	Poisoning by other psychodysleptics, accidental, initial encounter
T40993A	Poisoning by other psychodysleptics, assault, initial encounter
T40994A	Poisoning by other psychodysleptics, undetermined, initial encounter
T40995A	Adverse effect of other psychodysleptics, initial encounter
Z726	Gambling and betting

Code	Mental or substance use disorder
Mental disorder-related diagnoses	
Anxiety disorders	
F064	Anxiety disorder due to known physiological condition
F4000	Agoraphobia, unspecified
F4001	Agoraphobia with panic disorder
F4002	Agoraphobia without panic disorder
F4010	Social phobia, unspecified
F4011	Social phobia, generalized
F40210	Arachnophobia
F40218	Other animal type phobia
F40220	Fear of thunderstorms
F40228	Other natural environment type phobia
F40230	Fear of blood
F40231	Fear of injections and transfusions
F40232	Fear of other medical care
F40233	Fear of injury
F40240	Claustrophobia
F40241	Acrophobia
F40242	Fear of bridges
F40243	Fear of flying
F40248	Other situational type phobia
F40290	Androphobia
F40291	Gynephobia
F40298	Other specified phobia
F408	Other phobic anxiety disorders
F409	Phobic anxiety disorder, unspecified
F410	Panic disorder [episodic paroxysmal anxiety]
F411	Generalized anxiety disorder
F413	Other mixed anxiety disorders
F418	Other specified anxiety disorders
F419	Anxiety disorder, unspecified
F422	Mixed obsessional thoughts and acts
F423	Hoarding disorder
F424	Excoriation (skin-picking) disorder
F428	Other obsessive-compulsive disorder
F429	Obsessive-compulsive disorder, unspecified
F4311	Post-traumatic stress disorder, acute
F4312	Post-traumatic stress disorder, chronic
F930	Separation anxiety disorder of childhood
F940	Selective mutism
R466	Undue concern and preoccupation with stressful events
Bipolar disorders	
F0633	Mood disorder due to known physiological condition with manic features
F0634	Mood disorder due to known physiological condition with mixed features
F3010	Manic episode without psychotic symptoms, unspecified
F3011	Manic episode without psychotic symptoms, mild
F3012	Manic episode without psychotic symptoms, moderate

Code	Mental or substance use disorder
F3013	Manic episode, severe, without psychotic symptoms
F302	Manic episode, severe with psychotic symptoms
F303	Manic episode in partial remission
F308	Other manic episodes
F309	Manic episode, unspecified
F310	Bipolar disorder, current episode hypomanic
F3110	Bipolar disorder, current episode manic without psychotic features, unspecified
F3111	Bipolar disorder, current episode manic without psychotic features, mild
F3112	Bipolar disorder, current episode manic without psychotic features, mod
F3113	Bipolar disorder, current episode manic without psychotic features, severe
F312	Bipolar disorder, current episode manic severe with psychotic features
F3130	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified
F3131	Bipolar disorder, current episode depressed, mild
F3132	Bipolar disorder, current episode depressed, moderate
F314	Bipolar disorder, current episode depressed, severe, without psychotic features
F315	Bipolar disorder, current episode depressed, severe, with psychotic features
F3160	Bipolar disorder, current episode mixed, unspecified
F3161	Bipolar disorder, current episode mixed, mild
F3162	Bipolar disorder, current episode mixed, moderate
F3163	Bipolar disorder, current episode mixed, severe, without psychotic features
F3164	Bipolar disorder, current episode mixed, severe, with psychotic features
F3171	Bipolar disorder, in partial remission, most recent episode hypomanic
F3173	Bipolar disorder, in partial remission, most recent episode manic
F3175	Bipolar disorder, in partial remission, most recent episode depressed
F3177	Bipolar disorder, in partial remission, most recent episode mixed
F3181	Bipolar II disorder
F3189	Other bipolar disorder
F319	Bipolar disorder, unspecified
F340	Cyclothymic disorder
Depressive disorders	
F0630	Mood disorder due to known physiological condition, unspecified
F0631	Mood disorder due to known physiological condition with depressed features
F0632	Mood disorder due to physiological condition with major depressive-like episode
F320	Major depressive disorder, single episode, mild
F321	Major depressive disorder, single episode, moderate
F322	Major depressive disorder, single episode, severe without psychotic features
F323	Major depressive disorder, single episode, severe with psychotic features
F324	Major depressive disorder, single episode, in partial remission
F328	Other depressive episodes
F3281	Premenstrual dysphoric disorder
F3289	Other specified depressive episodes
F329	Major depressive disorder, single episode, unspecified
F330	Major depressive disorder, recurrent, mild
F331	Major depressive disorder, recurrent, moderate
F332	Major depressive disorder, recurrent severe without psychotic features
F333	Major depressive disorder, recurrent, severe with psychotic symptoms
F3341	Major depressive disorder, recurrent, in partial remission

Code	Mental or substance use disorder
F338	Other recurrent depressive disorders
F339	Major depressive disorder, recurrent, unspecified
F341	Dysthymic disorder
F348	Other persistent mood [affective] disorders
F3481	Disruptive mood dysregulation disorder
F3489	Other specified persistent mood disorders
F349	Persistent mood [affective] disorder, unspecified
F39	Unspecified mood [affective] disorder
O906	Postpartum mood disturbance
Disruptive, impulse-control, and conduct disorders	
F631	Pyromania
F632	Kleptomania
F6381	Intermittent explosive disorder
F6389	Other impulse disorders
F639	Impulse disorder, unspecified
F910	Conduct disorder confined to family context
F911	Conduct disorder, childhood-onset type
F912	Conduct disorder, adolescent-onset type
F913	Oppositional defiant disorder
F918	Other conduct disorders
F919	Conduct disorder, unspecified
Eating disorders	
F5000	Anorexia nervosa, unspecified
F5001	Anorexia nervosa, restricting type
F5002	Anorexia nervosa, binge eating/purging type
F502	Bulimia nervosa
F508	Other eating disorders
F5081	Binge eating disorder
F5089	Other specified eating disorder
F509	Eating disorder, unspecified
F9821	Rumination disorder of infancy
F9829	Other feeding disorders of infancy and early childhood
F983	Pica of infancy and childhood
Obsessive-compulsive disorders	
F42	Obsessive-compulsive disorder
F4521	Hypochondriasis
F4522	Body dysmorphic disorder
F633	Trichotillomania
R4681	Obsessive-compulsive behavior
Personality disorders	
F070	Personality change due to known physiological condition
F21	Schizotypal disorder
F600	Paranoid personality disorder
F601	Schizoid personality disorder
F602	Antisocial personality disorder
F603	Borderline personality disorder
F604	Histrionic personality disorder

Code	Mental or substance use disorder
F605	Obsessive-compulsive personality disorder
F606	Avoidant personality disorder
F607	Dependent personality disorder
F6081	Narcissistic personality disorder
F6089	Other specific personality disorders
F609	Personality disorder, unspecified
F6811	Factitious disorder with predominantly psychological signs and symptoms
F6812	Factitious disorder with predominantly physical signs and symptoms
F6813	Factitious disorder with combined psychological and physical signs and symptoms
F688	Other specified disorders of adult personality and behavior
F69	Unspecified disorder of adult personality and behavior
Schizophrenia and related disorders	
F060	Psychotic disorder with hallucinations due to known physiological condition
F061	Catatonic disorder due to known physiological condition
F062	Psychotic disorder with delusions due to known physiological condition
F200	Paranoid schizophrenia
F201	Disorganized schizophrenia
F202	Catatonic schizophrenia
F203	Undifferentiated schizophrenia
F205	Residual schizophrenia
F2081	Schizophreniform disorder
F2089	Other schizophrenia
F209	Schizophrenia, unspecified
F22	Delusional disorders
F23	Brief psychotic disorder
F24	Shared psychotic disorder
F250	Schizoaffective disorder, bipolar type
F251	Schizoaffective disorder, depressive type
F258	Other schizoaffective disorders
F259	Schizoaffective disorder, unspecified
F28	Other psychotic disorder not due to a substance or known physiological condition
F29	Unspecified psychosis not due to a substance or known physiological condition
Somatic symptom disorders	
F444	Conversion disorder with motor symptom or deficit
F445	Conversion disorder with seizures or convulsions
F446	Conversion disorder with sensory symptom or deficit
F447	Conversion disorder with mixed symptom presentation
F450	Somatization disorder
F451	Undifferentiated somatoform disorder
F4520	Hypochondriacal disorder, unspecified
F4529	Other hypochondriacal disorders
F4541	Pain disorder exclusively related to psychological factors
F4542	Pain disorder with related psychological factors
F458	Other somatoform disorders
F459	Somatoform disorder, unspecified
F54	Psychological and behavioral factors associated with disorders or diseases classified elsewhere

Code	Mental or substance use disorder
F6810	Factitious disorder, unspecified
Suicidal ideation or attempt	
R45851	Suicidal ideations
T1491	Suicide attempt (through fiscal year 2017)
T360X2A	Poisoning by penicillins, intentional self-harm, initial encounter
T361X2A	Poisoning by cephalosporins and other beta-lactam antibiotics, intentional self-harm, initial encounter
T362X2A	Poisoning by chloramphenicol group, intentional self-harm, initial encounter
T363X2A	Poisoning by macrolides, intentional self-harm, initial encounter
T364X2A	Poisoning by tetracyclines, intentional self-harm, initial encounter
T365X2A	Poisoning by aminoglycosides, intentional self-harm, initial encounter
T366X2A	Poisoning by rifampicins, intentional self-harm, initial encounter
T367X2A	Poisoning by antifungal antibiotics, systemically used, intentional self-harm, initial encounter
T368X2A	Poisoning by other systemic antibiotics, intentional self-harm, initial encounter
T3692XA	Poisoning by unspecified systemic antibiotic, intentional self-harm, initial encounter
T370X2A	Poisoning by sulfonamides, intentional self-harm, initial encounter
T371X2A	Poisoning by antimycobacterial drugs, intentional self-harm, initial encounter
T372X2A	Poisoning by antimalarials and drugs acting on other blood protozoa, intentional self-harm, initial encounter
T373X2A	Poisoning by other antiprotozoal drugs, intentional self-harm, initial encounter
T374X2A	Poisoning by anthelmintics, intentional self-harm, initial encounter
T375X2A	Poisoning by antiviral drugs, intentional self-harm, initial encounter
T378X2A	Poisoning by other specified systemic anti-infectives and antiparasitics, intentional self-harm, initial encounter
T3792XA	Poisoning by unspecified sys anti-infectives and antiparasitics, intentional self-harm, initial encounter
T380X2A	Poisoning by glucocorticoids and synthetic analogues, intentional self-harm, initial encounter
T381X2A	Poisoning by thyroid hormones and substitutes, intentional self-harm, initial encounter
T382X2A	Poisoning by antithyroid drugs, intentional self-harm, initial encounter
T383X2A	Poisoning by insulin and oral hypoglycemic drugs, intentional self-harm, initial encounter
T384X2A	Poisoning by oral contraceptives, intentional self-harm, initial encounter
T385X2A	Poisoning by other estrogens and progestogens, intentional self-harm, initial encounter
T386X2A	Poisoning by antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, intentional self-harm, initial encounter
T387X2A	Poisoning by androgens and anabolic congeners, intentional self-harm, initial encounter
T38802A	Poisoning by unspecified hormones and synthetic substitutes, intentional self-harm, initial encounter
T38812A	Poisoning by anterior pituitary hormones, intentional self-harm, initial encounter
T38892A	Poisoning by other hormones and synthetic substitutes, intentional self-harm, initial encounter
T38902A	Poisoning by unspecified hormone antagonists, intentional self-harm, initial encounter
T38992A	Poisoning by other hormone antagonists, intentional self-harm, initial encounter
T39012A	Poisoning by aspirin, intentional self-harm, initial encounter
T39092A	Poisoning by salicylates, intentional self-harm, initial encounter
T391X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter
T392X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter
T39312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T39392A	Poisoning by other nonsteroidal anti-inflammatory drugs, intentional self-harm, initial encounter
T394X2A	Poisoning by antirheumatics, not elsewhere classified, intentional self-harm, initial encounter
T398X2A	Poisoning by other nonopioid analgesics and antipyretics, not elsewhere classified, intentional self-harm, initial encounter
T3992XA	Poisoning by unspecified nonopioid analgesic, antipyretic and antirheumatic, intentional self-harm, initial encounter
T400X2A	Poisoning by opium, intentional self-harm, initial encounter
T401X2A	Poisoning by heroin, intentional self-harm, initial encounter
T402X2A	Poisoning by other opioids, intentional self-harm, initial encounter
T403X2A	Poisoning by methadone, intentional self-harm, initial encounter
T404X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter
T405X2A	Poisoning by cocaine, intentional self-harm, initial encounter
T40602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter
T40692A	Poisoning by other narcotics, intentional self-harm, initial encounter
T407X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter
T408X2A	Poisoning by lysergide, intentional self-harm, initial encounter
T40902A	Poisoning by unspecified psychodysleptics, intentional self-harm, initial encounter
T40992A	Poisoning by other psychodysleptics, intentional self-harm, initial encounter
T410X2A	Poisoning by inhaled anesthetics, intentional self-harm, initial encounter
T411X2A	Poisoning by intravenous anesthetics, intentional self-harm, initial encounter
T41202A	Poisoning by unspecified general anesthetics, intentional self-harm, initial encounter
T41292A	Poisoning by other general anesthetics, intentional self-harm, initial encounter
T413X2A	Poisoning by local anesthetics, intentional self-harm, initial encounter
T4142XA	Poisoning by unspecified anesthetic, intentional self-harm, initial encounter
T415X2A	Poisoning by therapeutic gases, intentional self-harm, initial encounter
T420X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter
T421X2A	Poisoning by iminostilbenes, intentional self-harm, initial encounter
T422X2A	Poisoning by succinimides and oxazolidinediones, intentional self-harm, initial encounter
T423X2A	Poisoning by barbiturates, intentional self-harm, initial encounter
T424X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter
T425X2A	Poisoning by mixed antiepileptics, intentional self-harm, initial encounter
T426X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T4272XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T428X2A	Poisoning by antiparkinsonism drugs and other central muscle-tone depressants, intentional self-harm, initial encounter
T43012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter
T43022A	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter
T431X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter
T43202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter
T43212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter
T43222A	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter
T43292A	Poisoning by other antidepressants, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T433X2A	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter
T434X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter
T43502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter
T43612A	Poisoning by caffeine, intentional self-harm, initial encounter
T43622A	Poisoning by amphetamines, intentional self-harm, initial encounter
T43632A	Poisoning by methylphenidate, intentional self-harm, initial encounter
T43692A	Poisoning by other psychostimulants, intentional self-harm, initial encounter
T438X2A	Poisoning by other psychotropic drugs, intentional self-harm, initial encounter
T4392XA	Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter
T440X2A	Poisoning by anticholinesterase agents, intentional self-harm, initial encounter
T441X2A	Poisoning by other parasympathomimetics, intentional self-harm, initial encounter
T442X2A	Poisoning by ganglionic blocking drugs, intentional self-harm, initial encounter
T443X2A	Poisoning by other parasympatholytics and spasmolytics, intentional self-harm, initial encounter
T444X2A	Poisoning by predominantly alpha-adrenoreceptor agonists, intentional self-harm, initial encounter
T445X2A	Poisoning by predominantly beta-adrenoreceptor agonists, intentional self-harm, initial encounter
T446X2A	Poisoning by alpha-adrenoreceptor antagonists, intentional self-harm, initial encounter
T447X2A	Poisoning by beta-adrenoreceptor antagonists, intentional self-harm, initial encounter
T448X2A	Poisoning by centrally-acting and adrenergic-neuron-blocking agents, intentional self-harm, initial encounter
T44902A	Poisoning by unspecified drugs primarily affecting the autonomic nervous system, intentional self-harm, initial encounter
T44992A	Poisoning by other drug primarily affecting the autonomic nervous system, intentional self-harm, initial encounter
T450X2A	Poisoning by anti-allergic and antiemetic drugs, intentional self-harm, initial encounter
T451X2A	Poisoning by antineoplastic and immunosuppressive drugs, intentional self-harm, initial encounter
T452X2A	Poisoning by vitamins, intentional self-harm, initial encounter
T453X2A	Poisoning by enzymes, intentional self-harm, initial encounter
T454X2A	Poisoning by iron and its compounds, intentional self-harm, initial encounter
T45512A	Poisoning by anticoagulants, intentional self-harm, initial encounter
T45522A	Poisoning by antithrombotic drugs, intentional self-harm, initial encounter
T45602A	Poisoning by unspecified fibrinolysis-affecting drugs, intentional self-harm, initial encounter
T45612A	Poisoning by thrombolytic drug, intentional self-harm, initial encounter
T45622A	Poisoning by hemostatic drug, intentional self-harm, initial encounter
T45692A	Poisoning by other fibrinolysis-affecting drugs, intentional self-harm, initial encounter
T457X2A	Poisoning by anticoagulant antagonists, vitamin K and other coagulants, intentional self-harm, initial encounter
T458X2A	Poisoning by other primarily systemic and hematological agents, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T4592XA	Poisoning by unspecified primarily systemic and hematological agent, intentional self-harm, initial encounter
T460X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter
T461X2A	Poisoning by calcium-channel blockers, intentional self-harm, initial encounter
T462X2A	Poisoning by other antidysrhythmic drugs, intentional self-harm, initial encounter
T463X2A	Poisoning by coronary vasodilators, intentional self-harm, initial encounter
T464X2A	Poisoning by angiotensin-converting-enzyme inhibitors, intentional self-harm, initial encounter
T465X2A	Poisoning by other antihypertensive drugs, intentional self-harm, initial encounter
T466X2A	Poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter
T467X2A	Poisoning by peripheral vasodilators, intentional self-harm, initial encounter
T468X2A	Poisoning by antivaricose drugs, including sclerosing agents, intentional self-harm, initial encounter
T46902A	Poisoning by unspecified agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter
T46992A	Poisoning by other agents primarily affecting the cardiovascular system, intentional self-harm, initial encounter
T470X2A	Poisoning by histamine H2-receptor blockers, intentional self-harm, initial encounter
T471X2A	Poisoning by other antacids and anti-gastric-secretion drugs, intentional self-harm, initial encounter
T472X2A	Poisoning by stimulant laxatives, intentional self-harm, initial encounter
T473X2A	Poisoning by saline and osmotic laxatives, intentional self-harm, initial encounter
T474X2A	Poisoning by other laxatives, intentional self-harm, initial encounter
T475X2A	Poisoning by digestants, intentional self-harm, initial encounter
T476X2A	Poisoning by antidiarrheal drugs, intentional self-harm, initial encounter
T477X2A	Poisoning by emetics, intentional self-harm, initial encounter
T478X2A	Poisoning by other agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter
T4792XA	Poisoning by unspecified agents primarily affecting gastrointestinal system, intentional self-harm, initial encounter
T480X2A	Poisoning by oxytocic drugs, intentional self-harm, initial encounter
T481X2A	Poisoning by skeletal muscle relaxants, intentional self-harm, initial encounter
T48202A	Poisoning by unspecified drugs acting on muscles, intentional self-harm, initial encounter
T48292A	Poisoning by other drugs acting on muscles, intentional self-harm, initial encounter
T483X2A	Poisoning by antitussives, intentional self-harm, initial encounter
T484X2A	Poisoning by expectorants, intentional self-harm, initial encounter
T485X2A	Poisoning by other anti-common-cold drugs, intentional self-harm, initial encounter
T486X2A	Poisoning by antiasthmatics, intentional self-harm, initial encounter
T48902A	Poisoning by unspecified agents prim act on the resp sys, intentional self-harm, initial encounter
T48992A	Poisoning by other agents primarily acting on the respiratory system, intentional self-harm, initial encounter
T490X2A	Poisoning by local antifungal, anti-infective and anti-inflammatory drugs, intentional self-harm, initial encounter
T491X2A	Poisoning by antipruritics, intentional self-harm, initial encounter
T492X2A	Poisoning by local astringents/detergents, intentional self-harm, initial encounter
T493X2A	Poisoning by emollients, demulcents and protect, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T494X2A	Poisoning by keratolytics, keratoplastics, and other hair treatment drugs and preparations, intentional self-harm, initial encounter
T495X2A	Poisoning by ophthalmological drugs and preparations, intentional self-harm, initial encounter
T496X2A	Poisoning by otorhinolaryngological drugs and preparations, intentional self-harm, initial encounter
T497X2A	Poisoning by dental drugs, topically applied, intentional self-harm, initial encounter
T498X2A	Poisoning by other topical agents, intentional self-harm, initial encounter
T4992XA	Poisoning by unspecified topical agent, intentional self-harm, initial encounter
T500X2A	Poisoning by mineralocorticoids and their antagonists, intentional self-harm, initial encounter
T501X2A	Poisoning by loop diuretics, intentional self-harm, initial encounter
T502X2A	Poisoning by carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, intentional self-harm, initial encounter
T503X2A	Poisoning by electrolytic, caloric and water-balance agents, intentional self-harm, initial encounter
T504X2A	Poisoning by drugs affecting uric acid metabolism, intentional self-harm, initial encounter
T505X2A	Poisoning by appetite depressants, intentional self-harm, initial encounter
T506X2A	Poisoning by antidotes and chelating agents, intentional self-harm, initial encounter
T507X2A	Poisoning by analeptics and opioid receptor antagonists, intentional self-harm, initial encounter
T508X2A	Poisoning by diagnostic agents, intentional self-harm, initial encounter
T50902A	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter
T50992A	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter
T50A12A	Poisoning by pertussis vaccine, including combinations with a pertussis component, intentional self-harm, initial encounter
T50A22A	Poisoning by mixed bacterial vaccines without a pertussis component, intentional self-harm, initial encounter
T50A92A	Poisoning by other bacterial vaccines, intentional self-harm, initial encounter
T50B12A	Poisoning by smallpox vaccines, intentional self-harm, initial encounter
T50B92A	Poisoning by other viral vaccines, intentional self-harm, initial encounter
T50Z12A	Poisoning by immunoglobulin, intentional self-harm, initial encounter
T50Z92A	Poisoning by other vaccines and biological substances, intentional self-harm, initial encounter
T510X2A	Toxic effect of ethanol, intentional self-harm, initial encounter
T511X2A	Toxic effect of methanol, intentional self-harm, initial encounter
T512X2A	Toxic effect of 2-Propanol, intentional self-harm, initial encounter
T513X2A	Toxic effect of fusel oil, intentional self-harm, initial encounter
T518X2A	Toxic effect of other alcohols, intentional self-harm, initial encounter
T5192XA	Toxic effect of unspecified alcohol, intentional self-harm, initial encounter
T520X2A	Toxic effect of petroleum products, intentional self-harm, initial encounter
T521X2A	Toxic effect of benzene, intentional self-harm, initial encounter
T522X2A	Toxic effect of homologues of benzene, intentional self-harm, initial encounter
T523X2A	Toxic effect of glycols, intentional self-harm, initial encounter
T524X2A	Toxic effect of ketones, intentional self-harm, initial encounter
T528X2A	Toxic effect of organic solvents, intentional self-harm, initial encounter
T5292XA	Toxic effect of unspecified organic solvent, intentional self-harm, initial encounter
T530X2A	Toxic effect of carbon tetrachloride, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T531X2A	Toxic effect of chloroform, intentional self-harm, initial encounter
T532X2A	Toxic effect of trichloroethylene, intentional self-harm, initial encounter
T533X2A	Toxic effect of tetrachloroethylene, intentional self-harm, initial encounter
T534X2A	Toxic effect of dichloromethane, intentional self-harm, initial encounter
T535X2A	Toxic effect of chlorofluorocarbons, intentional self-harm, initial encounter
T536X2A	Toxic effect of other halogen derivatives of aliphatic hydrocarbons, intentional self-harm, initial encounter
T537X2A	Toxic effect of other halogen derivatives of aromatic hydrocarbons, intentional self-harm, initial encounter
T5392XA	Toxic effect of unspecified halogen derivatives of aliphatic and aromatic hydrocarbons, intentional self-harm, initial encounter
T540X2A	Toxic effect of phenol and phenol homologues, intentional self-harm, initial encounter
T541X2A	Toxic effect of corrosive organic compounds, intentional self-harm, initial encounter
T542X2A	Toxic effect of corrosive acids and acid-like substances, intentional self-harm, initial encounter
T543X2A	Toxic effect of corrosive alkalis and alkali-like substances, intentional self-harm, initial encounter
T5492XA	Toxic effect of unspecified corrosive substance, intentional self-harm, initial encounter
T550X2A	Toxic effect of soaps, intentional self-harm, initial encounter
T551X2A	Toxic effect of detergents, intentional self-harm, initial encounter
T560X2A	Toxic effect of lead and its compounds, intentional self-harm, initial encounter
T561X2A	Toxic effect of mercury and its compounds, intentional self-harm, initial encounter
T562X2A	Toxic effect of chromium and its compounds, intentional self-harm, initial encounter
T563X2A	Toxic effect of cadmium and its compounds, intentional self-harm, initial encounter
T564X2A	Toxic effect of copper and its compounds, intentional self-harm, initial encounter
T565X2A	Toxic effect of zinc and its compounds, intentional self-harm, initial encounter
T566X2A	Toxic effect of tin and its compounds, intentional self-harm, initial encounter
T567X2A	Toxic effect of beryllium and its compounds, intentional self-harm, initial encounter
T56812A	Toxic effect of thallium, intentional self-harm, initial encounter
T56892A	Toxic effect of other metals, intentional self-harm, initial encounter
T5692XA	Toxic effect of unspecified metal, intentional self-harm, initial encounter
T570X2A	Toxic effect of arsenic and its compounds, intentional self-harm, initial encounter
T571X2A	Toxic effect of phosphorus and its compounds, intentional self-harm, initial encounter
T572X2A	Toxic effect of manganese and its compounds, intentional self-harm, initial encounter
T573X2A	Toxic effect of hydrogen cyanide, intentional self-harm, initial encounter
T578X2A	Toxic effect of inorganic substances, intentional self-harm, initial encounter
T5792XA	Toxic effect of unspecified inorganic substance, intentional self-harm, initial encounter
T5802XA	Toxic effect of carbon monoxide from motor vehicle exhaust, intentional self-harm, initial encounter
T5812XA	Toxic effect of carbon monoxide from utility gas, intentional self-harm, initial encounter
T582X2A	Toxic effect of carbon monoxide from incomplete combustion of other domestic fuels, intentional self-harm, initial encounter
T588X2A	Toxic effect of carbon monoxide from other source, intentional self-harm, initial encounter
T5892XA	Toxic effect of carbon monoxide from unspecified source, intentional self-harm, initial encounter
T590X2A	Toxic effect of nitrogen oxides, intentional self-harm, initial encounter
T591X2A	Toxic effect of sulfur dioxide, intentional self-harm, initial encounter
T592X2A	Toxic effect of formaldehyde, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T593X2A	Toxic effect of lacrimogenic gas, intentional self-harm, initial encounter
T594X2A	Toxic effect of chlorine gas, intentional self-harm, initial encounter
T595X2A	Toxic effect of fluorine gas and hydrogen fluoride, intentional self-harm, initial encounter
T596X2A	Toxic effect of hydrogen sulfide, intentional self-harm, initial encounter
T597X2A	Toxic effect of carbon dioxide, intentional self-harm, initial encounter
T59812A	Toxic effect of smoke, intentional self-harm, initial encounter
T59892A	Toxic effect of gases, fumes and vapors, intentional self-harm, initial encounter
T5992XA	Toxic effect of unspecified gases, fumes and vapors, intentional self-harm, initial encounter
T600X2A	Toxic effect of organophosphate and carbamate insecticides, intentional self-harm, initial encounter
T601X2A	Toxic effect of halogenated insecticides, intentional self-harm, initial encounter
T602X2A	Toxic effect of insecticides, intentional self-harm, initial encounter
T603X2A	Toxic effect of herbicides and fungicides, intentional self-harm, initial encounter
T604X2A	Toxic effect of rodenticides, intentional self-harm, initial encounter
T608X2A	Toxic effect of other pesticides, intentional self-harm, initial encounter
T6092XA	Toxic effect of unspecified pesticide, intentional self-harm, initial encounter
T6102XA	Ciguatera fish poisoning, intentional self-harm, initial encounter
T6112XA	Scombroid fish poisoning, intentional self-harm, initial encounter
T61772A	Other fish poisoning, intentional self-harm, initial encounter
T61782A	Other shellfish poisoning, intentional self-harm, initial encounter
T618X2A	Toxic effect of other seafood, intentional self-harm, initial encounter
T6192XA	Toxic effect of unspecified seafood, intentional self-harm, initial encounter
T620X2A	Toxic effect of ingested mushrooms, intentional self-harm, initial encounter
T621X2A	Toxic effect of ingested berries, intentional self-harm, initial encounter
T622X2A	Toxic effect of ingested (parts of) plant(s), intentional self-harm, initial encounter
T628X2A	Toxic effect of other specified noxious substances eaten as food, intentional self-harm, initial encounter
T6292XA	Toxic effect of unspecified noxious substances eaten as food, intentional self-harm, initial encounter
T63002A	Toxic effect of unspecified snake venom, intentional self-harm, initial encounter
T63012A	Toxic effect of rattlesnake venom, intentional self-harm, initial encounter
T63022A	Toxic effect of coral snake venom, intentional self-harm, initial encounter
T63032A	Toxic effect of taipan venom, intentional self-harm, initial encounter
T63042A	Toxic effect of cobra venom, intentional self-harm, initial encounter
T63062A	Toxic effect of venom of other North and South American snake, intentional self-harm, initial encounter
T63072A	Toxic effect of venom of Australian snake, intentional self-harm, initial encounter
T63082A	Toxic effect of venom of African and Asian snake, intentional self-harm, initial encounter
T63092A	Toxic effect of venom of snake, intentional self-harm, initial encounter
T63112A	Toxic effect of venom of gila monster, intentional self-harm, initial encounter
T63122A	Toxic effect of venom of venomous lizard, intentional self-harm, initial encounter
T63192A	Toxic effect of venom of reptiles, intentional self-harm, initial encounter
T632X2A	Toxic effect of venom of scorpion, intentional self-harm, initial encounter
T63302A	Toxic effect of unspecified spider venom, intentional self-harm, initial encounter
T63312A	Toxic effect of venom of black widow spider, intentional self-harm, initial encounter
T63322A	Toxic effect of venom of tarantula, intentional self-harm, initial encounter
T63332A	Toxic effect of venom of brown recluse spider, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T63392A	Toxic effect of venom of spider, intentional self-harm, initial encounter
T63412A	Toxic effect of venom of centipede/millipede, intentional self-harm, initial encounter
T63422A	Toxic effect of venom of ants, intentional self-harm, initial encounter
T63432A	Toxic effect of venom of caterpillars, intentional self-harm, initial encounter
T63442A	Toxic effect of venom of bees, intentional self-harm, initial encounter
T63452A	Toxic effect of venom of hornets, intentional self-harm, initial encounter
T63462A	Toxic effect of venom of wasps, intentional self-harm, initial encounter
T63482A	Toxic effect of venom of arthropod, intentional self-harm, initial encounter
T63512A	Toxic effect of contact with stingray, intentional self-harm, initial encounter
T63592A	Toxic effect of contact with other venomous fish, intentional self-harm, initial encounter
T63612A	Toxic effect of contact with Portugese Man-o-war, intentional self-harm, initial encounter
T63622A	Toxic effect of contact with other jellyfish, intentional self-harm, initial encounter
T63632A	Toxic effect of contact with sea anemone, intentional self-harm, initial encounter
T63692A	Toxic effect of contact with other venom marine animals, intentional self-harm, initial encounter
T63712A	Toxic effect of contact with venom marine plant, intentional self-harm, initial encounter
T63792A	Toxic effect of contact with other venomous plant, intentional self-harm, initial encounter
T63812A	Toxic effect of contact with venomous frog, intentional self-harm, initial encounter
T63822A	Toxic effect of contact with venomous toad, intentional self-harm, initial encounter
T63832A	Toxic effect of contact with other venomous amphib, intentional self-harm, initial encounter
T63892A	Toxic effect of contact with other venom animals, intentional self-harm, initial encounter
T6392XA	Toxic effect of contact with unspecified venom animal, intentional self-harm, initial encounter
T6402XA	Toxic effect of aflatoxin, intentional self-harm, initial encounter
T6482XA	Toxic effect of mycotoxin food contaminants, intentional self-harm, initial encounter
T650X2A	Toxic effect of cyanides, intentional self-harm, initial encounter
T651X2A	Toxic effect of strychnine and its salts, intentional self-harm, initial encounter
T65212A	Toxic effect of chewing tobacco, intentional self-harm, initial encounter
T65222A	Toxic effect of tobacco cigarettes, intentional self-harm, initial encounter
T65292A	Toxic effect of tobacco and nicotine, intentional self-harm, initial encounter
T653X2A	Toxic effect of nitroderivatives and aminoderivatives of benzene and its homologues, intentional self-harm, initial encounter
T654X2A	Toxic effect of carbon disulfide, intentional self-harm, initial encounter
T655X2A	Toxic effect of nitroglycerin and other nitric acids and esters, intentional self-harm, initial encounter
T656X2A	Toxic effect of paints and dyes, not elsewhere classified, intentional self-harm, initial encounter
T65812A	Toxic effect of latex, intentional self-harm, initial encounter
T65822A	Toxic effect of harmful algae and algae toxins, intentional self-harm, initial encounter
T65832A	Toxic effect of fiberglass, intentional self-harm, initial encounter
T65892A	Toxic effect of other substances, intentional self-harm, initial encounter
T6592XA	Toxic effect of unspecified substance, intentional self-harm, initial encounter
T71112A	Asphyxiation due to smothering under pillow, intentional self-harm, initial encounter
T71122A	Asphyxiation due to plastic bag, intentional self-harm, initial encounter
T71132A	Asphyxiation due to being trapped in bed linens, intentional self-harm, initial encounter
T71152A	Asphyxiation due to smothering in furniture, intentional self-harm, initial encounter
T71162A	Asphyxiation due to hanging, intentional self-harm, initial encounter

Code	Mental or substance use disorder
T71192A	Asphyxiation due to mechanical threat to breathing due to other causes, intentional self-harm, initial encounter
T71222A	Asphyxiation due to being trapped in a car trunk, intentional self-harm, initial encounter
T71232A	Asphyxiation due to being trapped in a (discarded) refrigerator, intentional self-harm, initial encounter
X710XXA	Intentional self-harm by drowning and submersion while in bathtub, initial encounter
X711XXA	Intentional self-harm by drowning and submersion while in swimming pool, initial encounter
X712XXA	Intentional self-harm by drowning and submersion after jump into swimming pool, initial encounter
X713XXA	Intentional self-harm by drowning and submersion in natural water, initial encounter
X718XXA	Other intentional self-harm by drowning and submersion, initial encounter
X719XXA	Intentional self-harm by drowning and submersion, unspecified, initial encounter
X720XXA	Intentional self-harm by handgun discharge, initial encounter
X730XXA	Intentional self-harm by shotgun discharge, initial encounter
X731XXA	Intentional self-harm by hunting rifle discharge, initial encounter
X732XXA	Intentional self-harm by machine gun discharge, initial encounter
X738XXA	Intentional self-harm by other larger firearm discharge, initial encounter
X739XXA	Intentional self-harm by unspecified larger firearm discharge, initial encounter
X7401XA	Intentional self-harm by airgun, initial encounter
X7402XA	Intentional self-harm by paintball gun, initial encounter
X7409XA	Self-harm by other gas, air or spring-operated gun, initial encounter
X748XXA	Intentional self-harm by other firearm discharge, initial encounter
X749XXA	Intentional self-harm by unspecified firearm discharge, initial encounter
X750XXA	Intentional self-harm by explosive material, initial encounter
X760XXA	Intentional self-harm by smoke, fire and flames, initial encounter
X770XXA	Intentional self-harm by steam or hot vapors, initial encounter
X771XXA	Intentional self-harm by hot tap water, initial encounter
X772XXA	Intentional self-harm by other hot fluids, initial encounter
X773XXA	Intentional self-harm by hot household appliances, initial encounter
X778XXA	Intentional self-harm by other hot objects, initial encounter
X779XXA	Intentional self-harm by unspecified hot objects, initial encounter
X780XXA	Intentional self-harm by sharp glass, initial encounter
X781XXA	Intentional self-harm by knife, initial encounter
X782XXA	Intentional self-harm by sword or dagger, initial encounter
X788XXA	Intentional self-harm by other sharp object, initial encounter
X789XXA	Intentional self-harm by unspecified sharp object, initial encounter
X790XXA	Intentional self-harm by blunt object, initial encounter
X800XXA	Intentional self-harm by jumping from a high place, initial encounter
X810XXA	Intentional self-harm by jumping or lying in front of motor vehicle, initial encounter
X811XXA	Self-harm by jumping or lying in front of (subway) train, initial encounter
X818XXA	Self-harm by jumping or lying in front of moving object, initial encounter
X820XXA	Intentional collision of motor vehicle with other motor vehicle, initial encounter
X821XXA	Intentional collision of motor vehicle with train, initial encounter
X822XXA	Intentional collision of motor vehicle with tree, initial encounter
X828XXA	Other intentional self-harm by crashing of motor vehicle, initial encounter
X830XXA	Intentional self-harm by crashing of aircraft, initial encounter
X831XXA	Intentional self-harm by electrocution, initial encounter

Code	Mental or substance use disorder
X832XXA	Intentional self-harm by exposure to extremes of cold, initial encounter
X838XXA	Intentional self-harm by other specified means, initial encounter
Trauma- and stressor-related disorders	
F430	Acute stress reaction
F4310	Post-traumatic stress disorder, unspecified
F4320	Adjustment disorder, unspecified
F4321	Adjustment disorder with depressed mood
F4322	Adjustment disorder with anxiety
F4323	Adjustment disorder with mixed anxiety and depressed mood
F4324	Adjustment disorder with disturbance of conduct
F4325	Adjustment disorder with mixed disturbance of emotions and conduct
F4329	Adjustment disorder with other symptoms
F438	Other reactions to severe stress
F439	Reaction to severe stress, unspecified
F440	Dissociative amnesia
F441	Dissociative fugue
F442	Dissociative stupor
F4481	Dissociative identity disorder
F4489	Other dissociative and conversion disorders
F449	Dissociative and conversion disorder, unspecified
F941	Reactive attachment disorder of childhood
F942	Disinhibited attachment disorder of childhood
Miscellaneous mental disorders	
F068	Other mental disorders due to known physiological condition
F09	Unspecified mental disorder due to known physiological condition
F481	Depersonalization-derealization syndrome
F488	Other specified nonpsychotic mental disorders
F489	Nonpsychotic mental disorder, unspecified
F650	Fetishism
F651	Transvestic fetishism
F652	Exhibitionism
F653	Voyeurism
F654	Pedophilia
F6551	Sexual masochism
F6552	Sexual sadism
F6581	Frotteurism
F6589	Other paraphilias
F659	Paraphilia, unspecified
F939	Childhood emotional disorder, unspecified
F99	Mental disorder, not otherwise specified
O99340	Other mental disorders complicating pregnancy, unspecified trimester
O99341	Other mental disorders complicating pregnancy, first trimester
O99342	Other mental disorders complicating pregnancy, second trimester
O99343	Other mental disorders complicating pregnancy, third trimester
O99344	Other mental disorders complicating childbirth
O99345	Other mental disorders complicating the puerperium
R45850	Homicidal ideations